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Abstract 
 
Cancer is the second leading cause of death worldwide and many cancer subtypes 
remain poorly understood. Most conventional chemotherapeutic treatments are still 
associated with life-threatening toxic side effects that primarily result from a lack of 
specificity directed towards cancer cells. Recent breakthroughs in genomic and 
transcriptomic sequencing technologies have allowed the molecular profiling of 
thousands of tumors in different cancer types. It has become evident that cancer 
cannot be considered a singular disease and that its manifestations cannot 
exclusively be explained by the accumulation of genetic mutations. Instead, 
epigenetic and proteomic changes as well as posttranslational modifications (PTMs) 
of proteins are crucial drivers of oncogenesis. In this thesis, I investigated system-
wide alterations in cancer at several biological and cellular levels using mass 
spectrometry (MS). Starting from the nucleus of the cell, I explored the epigenetic 
changes in lymphoma at the biotechnology company Genentech Inc. We found that 
the methyltransferase EZH2 is the most significantly over-expressed epigenetic 
regulator in cancer, and is co-regulated with a cell cycle network. Zooming out from 
the nuclear level, I analyzed phosphorylation-signaling alterations in primary and 
secondary glioblastoma cell line models at the University of California, San 
Francisco (UCSF). Here, I focused on the interplay between the MAPK and PI3K 
signaling cascades. At the Max Planck Institute (MPI) of Biochemistry, I moved on 
to translational proteomics, working with human cancer tissues. I optimized an MS-
based proteomic workflow for the rapid screening of clinical tissue samples and 
showed that MS-based proteomics can be used for novel therapeutic target 
identification in end-stage chemorefractory cancer patients. 
Through its industrial, academic and clinical perspective on a variety of proteomic 
methods, this PhD thesis demonstrates that MS-based proteomics is applicable to 
personalized oncology. My hope is that this unique resource of the identity, quantity, 
and alterations of proteins, phosphosites and histone PTMs, may reveal new 
insights into the field of oncology.
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I) Introduction 
 
1. The proteome and its large scale investigation by mass 
spectrometry 
 
Each cell is a genuine masterpiece. Biological information is transcribed from DNA 
to RNA and finally translated into proteins. These proteins may be further modified 
post translationally, leading to intricate signaling patterns within and between 
different cell types. Recent breakthroughs in DNA and RNA sequencing 
technologies allow the molecular profiling of essentially complete genomes and 
transcriptomes1. While these methodologies have revolutionized our understanding 
of a vast array of human diseases, including cancer, fundamental mechanisms are 
not only driven by genetic or transcriptomic alterations. Instead, they only manifest 
clinically if they involve changes at the protein level as well. Proteins are the 
paramount active biological entities in cells and work in concert with each other and 
other biomolecules as molecular machines, ensuring that each cell generates 
energy, communicates with its environment, divides, moves, performs its specific 
biological functions, or commits apoptosis. The full complement of proteins in a 
biological system is termed the proteome, while proteomics refers to the large-scale 
investigation of the proteome using a variety of technologies. The unceasing 
development of ever more powerful proteomic methods over the last decades now 
enables the analysis of proteomes in great depth. As a result, the investigation of 
complex biological functions and promising clinical applications are becoming 
realistic2. 
 
1.1 The human proteome 
 
With approximately 20,000 protein-coding genes, the human genome is five times 
smaller than that of an onion in terms of genome size. Thus, the number of genes 
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alone does not determine the complexity of an organism. Additional biological 
differences originate from the regulation of the genes, alternative splicing, protein 
localization and interactions. The human proteome, in particular, is diversified by 
many protein variations (isoforms), and posttranslational modifications (PTMs), 
which alone add at least another order of magnitude of complexity. More than 90% 
of the human genes are spliced3 and altogether, more than 300 types of PTMs have 
been described4. Combined, these modifications yield millions of different possible 
‘proteoforms’5, resulting in a dramatic increase in the complexity of the human 
proteome. Among these PTMs, many have been shown to regulate normal and 
pathogenic cell biological functions. The most common covalent modifications are 
phosphorylation, ubiquitination, acetylation, glycosylation and methylation and 
together they vastly increase the functional diversity of proteins. Among the some 
300,000 human PTM sites that have so far been recorded in the PhosphositePlus 
database6, only a small percentage have been assigned to regulatory or biological 
functions. Additionally, proteins are often modified at multiple sites, either through a 
combinatorial or sequential addition of functional groups.  
Mass spectrometry (MS)-based proteomics has evolved into the method of choice 
for the large-scale identification and quantitation of nearly all expressed proteins as 
well as their site-specific PTMs2,7. Phosphorylation is the most extensively studied 
PTM because it is a key modulator of cellular signal transduction. MS-based 
quantitative phosphoproteomics has already revealed site-specific phosphorylation 
dynamics after EGF stimulation8, identified molecular switches underlying FGFR 
cellular responses9, oncogenic signaling in the MAPK and PI3K pathways (Article 
3), and ‘druggable’ kinases10. These examples among many highlight the potential 
of MS-based phosphoproteomics to improve our understanding of molecular 
mechanisms, identify clinically relevant biomarkers and uncover potential 
therapeutic targets. 
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1.2. Mass spectrometry-based proteomics 
1.2.1. Mass spectrometry history 
 
Mass spectrometry (MS) is a technology that determines the mass/charge (m/z) 
ratios of ions for which Thompson (Th) is the proper unit. Based on the charge state 
of an ion, the m/z ratios can be converted to its molecular mass with a standard unit 
of Dalton (Da). The analyte of interest (peptides in this thesis) must first be ionized 
in its intact form, as this is essential for its identification and quantification. This is 
difficult for labile biomolecules but this obstacle was overcome with the development 
of two soft ionization techniques (electrospray ionization (ESI) and matrix-assisted 
laser desorption ionization (MALDI)) in 1988. In ESI, for which John Fenn received 
a share of the Nobel Prize in Chemistry in 2002, analytes are directly vaporized and 
ionized from a liquid phase using a high voltage via rapid solvent evaporation11,12. 
As the solvent of the droplet evaporates, the charge density increases, resulting in 
a stream of charged ions that are transferred into the vacuum of the mass 
spectrometer. ESI has become particularly popular since it can directly be coupled 
to a liquid chromatography (LC) system, which is ideal suited to the analysis of 
complex protein and peptide mixtures. Subsequent technological advances 
included the miniaturization of ESI in the form of the particularly sensitive, low-flow 
nano-electrospray13. 
 
1.2.2. Top-down vs. bottom-up proteomics 
 
Conceptually, there are two MS-based proteomic strategies, termed ‘top-down’ and 
‘bottom-up’. In top-down proteomics, intact proteins are analyzed, typically in 
purified form14. This can be beneficial for the comprehensive analysis of protein 
isoforms, complex PTM conformations, and especially therapeutic antibodies. While 
theoretically appealing, top-down measurements, remain experimentally and 
computationally challenging because high molecular weight compounds are not 
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very sensitively ionized and their complex charge patterns render the MS and 
MS/MS spectra difficult to acquire and interpret. In contrast, bottom-up proteomics 
entails the digestion of proteins using sequence specific proteases into peptides, 
leading to much simpler MS analysis. Bottom-up or ‘shotgun’ proteomics has 
become the standard method for large-scale proteome analysis and has been 
broadly applied to the analysis of in-depth and cell-type-resolved proteomes. In this 
thesis, this advance has allowed me to map the human heart to unprecedented 
depth (Article 6). 
 
1.2.3. From cells or tissues to proteomes: Bottom-up proteomic 
workflows 
 
A typical bottom-up MS-based proteomics workflow consists of three main steps: 
sample preparation, including protein digestion, the LC-MS measurement itself, and 
subsequent data analysis (Figure 1). Apart from providing a general overview, I here 
particularly focus on developments from our laboratory and those applied to the 
projects in this thesis. 
 
5 
 
 
Figure 1 The bottom-up MS-based proteomic workflow A) Sample preparation consists 
of protein extraction, digestion and optional PTM enrichment. B) HPLC and online MS 
measurement. C) Data analysis includes peptide identification and quantification, assembly 
into proteins and subsequent bioinformatic analysis. Adapted from15. 
 
Sample preparation includes the extraction of proteins from biological material and 
their digestion into peptides. These peptides are then subjected to separation by 
reversed phase high pressure LC (HPLC) based on their different strengths of 
hydrophobic interaction with a stationary phase, typically C18 modified silica. As the 
peptides elute from the chromatographic column, they are ionized via ESI and 
transferred into the mass spectrometer. The generated mass spectra provide 
information about the abundance (intensity) and the identity (amino acid sequence 
and PTMs) of the peptide. 
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1.2.4. Sample preparation: From ‘in-gel’ to ‘in-solution’, and ‘in-
StageTip’ 
 
The first step of the proteomic workflow, sample preparation, is a crucial procedure 
of MS-based proteomics. Sample preparation protocols have to be adapted to the 
source and the amount of material. In biological research, proteins have been 
analyzed mainly by 1D SDS polyacrylamide gel electrophoresis, a procedure that 
employs detergent-mediated (e.g. sodium dodecyl sulfate (SDS)) solubilization of 
the sample followed by SDS polyacrylamide gel electrophoresis. The development 
of in-gel digestion, in which proteins that are still present in the gel, are directly 
degraded by trypsin, paved the way for MS sample preparation that was 
immediately useful to biologists16,17. By combining in-gel digestion with nano-
electrospray, MS became applicable for the first time to proteomics18,19. This 
procedure also permits fractionation of the proteome through the excision of the 
entire 1D gel in a chosen number of ranges. The development of Stop And Go 
Extraction tips (StageTips) allowed convenient sample handling, even of minimal 
sample amounts and optional peptide fractionation20. Subsequently, improved LC-
MS performance made it possible to move from time-consuming in-gel digestion to 
in-solution digestion21,22. In-solution digestion employs chaotropic agents, such as 
urea, for protein extraction and digestion under denaturing conditions. This has the 
advantage of directly extracting, denaturing, and digesting the proteins in the lysis 
buffer. High concentrations of urea, however, are associated with decreased 
digestion efficiency and such weak agents do not solubilize membrane proteins, for 
instance. The ‘Filter-Aided Sample Preparation’ (FASP) allows removal of the 
detergents or chaotropic agents by trapping the denatured proteins on a spin-filter 
matrix, enabling efficient enzymatic digestion23. The next step was the ‘in-StageTip’ 
protocol, as it permitted the robust preparation of samples in high-throughput, using 
robotic assistance. In-StageTip digestion employs somewhat milder detergents than 
SDS, such as sodium deoxycholate (SDC), which is particularly suitable for efficient 
cell lysis, reduction, alkylation and protein digestion in a single device. These 
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sample preparation developments resulted in a considerably reduced sample 
preparation time, contamination, and loss24. 
All sample preparation protocols first require the lysis of the biological source 
material in order to efficiently extract proteins. This step can also require mechanical 
breakdown, such as sonication, bead-milling or heating to increase lysis efficiency. 
The cysteines of the extracted proteins are then reduced and alkylated to disrupt 
disulfide bridges prior to digestion. The alkylation step prevents the reduced reactive 
thiol groups from reforming disulfide bridges. Typical reducing agents include tris(2-
carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT), while the most commonly 
used alkylating agents are iodoacetamide (IAM) or chloroacetic acid (CAA). For the 
proteolytic digestion of proteins, trypsin is the enzyme of choice due to its high 
cleavage specificity C-terminal to lysines and arginines, generating an average 
peptide length of 14 amino acids25. The advantages of sequence specific digestion 
enzymes include the generation of a limited and defined set of peptides, placing a 
positive charge at the C-terminus in case of trypsin, and providing constraints in the 
bioinformatic identification of peptides26. In some cases, however, the resulting 
tryptic peptides might be too long or too short for effective MS analysis. Other 
enzymes can then be employed, such as chymotrypsin, AspN, Lys-N, Lys-C, Arg-
C, or Glu-C to increase the diversity of generated peptides, and to boost overall 
protein sequence coverage27. Other methods preventing the generation of too short 
or hydrophilic peptides include chemical modification of lysines by propionic 
anhydride to neutralize charges and block lysine residues28,29. This labeling 
approach is particularly suitable for bottom-up analysis of histone tails using trypsin 
as it improves sequence coverage across the lysine- and arginine-rich tails that 
harbor most modifications, as applied in article 2. 
 
1.2.5. PTM-enrichment strategies 
 
The analysis of the entire proteomes of cells or tissues is already challenging. 
Conceptually and practically, biological processes involving regulatory PTMs that 
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feature substoichometric modifications are even more difficult and in practice always 
require additional enrichment steps during sample preparation. Common PTM 
enrichment strategies use affinity purification based on charge properties or 
antibody recognition. These are usually applied at the peptide level, ensuring higher 
accessibility of PTMs – allowing specific binding. The importance of phosphorylation 
has engendered highly effective protocols and approximately 240,000 human 
phosphorylation sites have been reported so far6. During the lysis of the samples, 
additional phosphatase inhibitors are generally added to prevent the 
dephosphorylation of the proteins during sample handling. Global analysis of serine- 
and threonine-phosphorylation (pS and pT) is commonly achieved by metal ion-
based enrichment methods such as immobilized metal affinity chromatography 
(IMAC) or titanium dioxide (TiO2). They rely on the interaction between the 
negatively charged phosphate groups and the positively charged iron (Fe) or 
titanium (Ti) ions, respectively (Figure 2). Non-phosphorylated peptides are washed 
away in the presence of salt to reduce non-specific binding of highly acidic peptides. 
Phosphopeptides are subsequently eluted with potassium phosphate to disrupt the 
phospho-Fe or -TiO2 interactions. While initially phosphorylation enrichment 
required large starting material in the mg-range, workflow optimizations now allow 
the analysis of more than 10,000 phosphosites from minimal starting material in a 
96-well format30. Multiphosphorylated peptides, however, remain challenging to 
assign and quantify unambiguously. To this end, the combination of IMAC with TiO2 
(termed SIMAC) helps by efficienty separating of mono-phosphorylated from 
multiply phosphorylated peptides31. Alternative methods that also increase the 
identification of multiply phosphorylated peptides include preferential binding to 
graphite powder or Ti(4+)32,33. 
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Figure 2 TiO2 and IMAC phosphopeptide enrichment strategies. 
Global phosphorylation distributions revealed that about 93%, 6%, and 1% of 
phosphorylated sites occur on serine, threonine, and tyrosine, respectively (Figure 
3) consistent with previous observations8. Although phosphotyrosines (pY) are 
present at even lower site occupancies than pS and pT overal, they activate receptor 
tyrosine kinases (RTKs) and play pivotal role in multiple diseases, including cancer. 
For optimal identification of pY-containing peptides, they are purified from the 
mixture of digested peptides by specific immuno-capture. For instance, the 
combination of the recently developed P-Tyr-1000 antibody (Cell Signaling 
Technology) with LC-MS/MS analysis, has recently resulted in the identification of 
several hundreds of pY sites in colorectal cancer cells with a very high enrichment 
specificity34,35. 
Antibody-based enrichment strategies have been extended to the quantitative 
analysis of ubiquitinations, methylations, and acetylations. In particular, the 
development of anti-di-glycine remnant antibodies led to the identification of more 
than 10,000 ubiquitination sites36,37. Furthermore, antibodies separately targeting 
mono-, di-, and tri- methylated lysines or mono- and di-methylated arginines 
peptides have been applied to map the human methylome in great depth38. 
Proteome-wide acetylation analyses have likewise been made possible by antibody-
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based enrichment and have uncovered pivotal cellular processes that are regulated 
by acetylation39. 
In addition to charge- or antibody-based enrichment strategies, enzyme-based 
enrichment can uncover proteolytic sites of biologicals of interest. For example, the 
subtiligase approach enabled the identification of more than 8,000 proteolytic sites, 
including 1,700 caspase cleavage sites in human cells40. 
  
 
Figure 3 distribution of phosphorylation events in HCT116 cells, A) Distribution of single, 
doubly, triply and quadruply phosphorylated peptides B) Distribution of phosphorylated sites 
per amino acid. (Data generated by the author). 
 
1.2.6. Peptide fractionation for deep quantitative proteomes 
 
In principle, protein level fractionation would be attractive but in practice it is 
hampered by solubility issues and low resolution41. To reach deep proteome 
coverage in complex biological samples, an additional step of peptide fractionation 
is applied prior to LC-MS measurements. Here, tryptic peptides are separated into 
different fractions based on principles such as high pH reversed-phase fractionation 
or strong cation exchange (SCX). Since the peptides are separated from each other 
– decreasing complexity in LC-MS and more material can be injected onto the 
analytical column in total, pre-fractionation will increase overall detectability of low 
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abundance peptides, leading to increased proteome depth and sequence coverage. 
Off-line high pH reversed-phase fractionation combined with the low pH of the online 
LC-MS has become popular because it tends to yield overall better peptide 
identifications than using SCX42. This is mainly due to the fact that individual first 
dimension fractions are pooled from different parts of the gradient (‘concatenation’), 
effectively providing orthogonal separation (meaning that peptide retention times 
are not correlating)43–45. However, because of the large diameter of the C18 columns 
used for fractionation, such approaches required starting material in the mg-range 
and the concatenation of the different fractions was generally done manually (Article 
3). To make the fractionation more streamlined, our group has developed a ‘loss-
less nano-spider’ fractionator, which enables the fractionation of very low-µg starting 
material and automatically concatenates the collected fractions via a rotating 
valve46. In cell lines, this approach resulted in the quantification of almost 12,000 
proteins using 24 fractions. In article 6, I applied spider fractionation for the first time 
to tissues and quantified over 10,000 proteins in a very challenging sample. 
 
1.2.7. Liquid chromatography-mass spectrometry 
 
The (fractionated) peptide mixtures are then subjected to HPLC separation, which 
is based on the different hydrophobic interaction with a stationary phase, typically 
C18-silica. Peptides elute in a time dependent manner by a linear increase of an 
organic solvent such as acetonitrile. As the peptides elute from the chromatographic 
column, they are ionized via ESI. The better the chromatographic resolution, the 
lower the number of co-eluting peptides and the higher their concentration. This 
makes very long columns and very small particle sizes attractive, albeit at the cost 
of extremely high pressures. For instance, our group uses 75 µm inner diameter 
columns with 50 cm lengths, filled with sub-2 µm particles and requiring a pump 
pressure of more than 1,000 bar. To improve the ionization efficiency, formic acid is 
added to the solvent to provide a source of protons. The addition of the polar aprotic 
dimethylsulfoxide (DMSO) solvent further enhances the ionization and has been 
12 
 
reported to increase peptide signals47. We also observed this increase in sensitivity 
in the heart atlas (Article 6), where I used 5% DMSO containing solvents for the LC-
MS/MS measurements. After the ionization step, the resulting charged ions are 
transferred via an ion transfer tube to the vacuum region of the instrument. The 
mass analyzer of the mass spectrometer then assigns m/z and intensity values to 
the eluting peptides. They include quadrupole, time-of-flight (TOF), ion trap and 
Orbitrap analyzers. Quadrupoles are characterized by high reproducibility and high 
sensitivity but poor resolution and speed. TOF instruments have the highest 
scanning speed but until recently suffered from comparatively low mass resolution. 
Orbitraps are the most commonly used mass analyzer in proteomics today due to 
their high resolution, sensitivity and accurate mass capabilities48. The Orbitrap is 
composed of one central spindle and two outer electrodes. It captures ions by 
‘electrodynamic squeezing’ resulting from rapidly dropping the voltage on the central 
electrode. The ions subsequently oscillate around the central electrode and the 
frequency of oscillation is proportional to the square root of the mass of the ions. 
The time varying signal (the ‘transient’) is subsequently Fourier transformed (FT), 
converting the waveform of the ions into mass spectra. Coupling FT to a phased 
spectrum deconvolution method (ΦSDM) has been recently shown to result in 
doubling of the mass resolution, enabling the use of shorter transients and 
consequently faster analysis cycles. However, this exciting method requires 
extremely high computational power and is therefore not implemented on a broad 
scale yet49. 
As the peptide mass alone does not permit its complete characterization, a second 
step of mass spectrometry, termed tandem MS, MS2 or MS/MS, is needed. While, 
the MS1 scan yields the m/z values of the precursor ions (intact peptides), the MS2 
scans result in the m/z values and intensities of their fragments. The analysis cycles 
in shotgun proteomics consists of selecting the TopN most abundant peptides from 
each MS1 scan (also termed survey of full scan) and subsequently fragmenting 
them to generate the MS2 scans. Cycle times can be selected by choosing the 
number of peaks to fragment (N) and – in Orbitrap analysis –the transient times for 
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MS1 and MS2 scans. To ensure fragmentation of peaks with very short elution 
times, they should not exceed one or a few seconds.  
 
1.2.8. Fragmentation strategies 
 
The selection of appropriate fragmentation methods, such as collision-induced 
dissociation (CID), higher energy collisional dissociation (HCD), or electron-transfer 
dissociation (ETD) is important for the optimal generation of sequence ion series 
required for peptide identification and unambiguous PTM site assignments. The 
peptide or protein precursor ions are positively charged, with protonation sites 
usually at the amino-terminus and the basic amino-acid residues and in CID, they 
undergo collisions by interactions with inert gas molecules, such as helium. This 
induces vibronic activation, leading to peptide bond dissociation and generating 
primarily N-terminal b- and C-terminal y-type ions50,51 (Figure 4). The CID process 
in ion trap is generally more effective for small and low-charge state peptides but is 
strongly influenced by the amino acid sequence and the distribution of the positive 
charges along the peptide backbone. HCD is a similar strategy of fragmentation as 
CID but is characterized by higher activation energy compared to CID. The higher 
fragmentation efficiency for HCD predominantly results in y-type fragment ions52. 
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Figure 4 Different fragmentation strategies lead to formation of different ion species. While 
CID and HCD based fragmentation generate b- and y-type ions, ETD leads to the formation 
of c- and z-type ions (adapted from53). 
When comparing HCD coupled to an Orbitrap analyzer to ion trap fragmentation 
and detection, HCD produces higher quality spectra because of the superior 
resolution and mass accuracy. Spectral acquisition times, however, are longer 
compared to CID, because more ions need to accumulate to generate a signal by 
image current detection in the Orbitrap. For phosphoproteomic analysis, both CID 
and HCD induce so called ‘neutral losses’, meaning that uncharged phosphorylation 
moieties are cleaved from their precursor peptides, creating a -98 Da (H3PO4) mass 
shift. It is debated which of CID or HCD is more appropriate for phosphorylation 
analysis, but clearly HCD improves the formation of rich fragment ion spectra for 
phosphopeptides54. ETD achieves fragmentation through neutralization of 
backbone protonation sites with radical anions, used as the electron transfer 
species, but generally at lower efficiency than CID or HCD. The resulting random 
nonergodic N–Cα backbone bonds breaks generate c- and z-type fragment ions55. 
ETD is more effective for large, multi-charge state peptides and is particularly 
suitable for detecting labile PTMs because peptide backbone fragmentation is 
virtually independent of the amino acid sequence. For example, O-GlcNAc 
elimination does not occur using ETD56. 
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1.2.9. Mass spectrometer types 
 
Major developments during the last decade have led to new high performance 
instrumentation that provide both high resolution and high mass measurement 
accuracies for MS1 and MS2 levels. Resolution is the ability to distinguish two peaks 
of different m/z ratio (modern instruments can resolve peaks down to 1 mDa at mass 
1,000), whereas mass accuracy describes the difference between measured and 
theoretical mass. The high quality mass spectra that are typical today have 
increased the reliability and efficiency of protein identification at the peptide level. 
In this thesis, all measurements were performed on Thermo Fisher Scientific 
Orbitrap mass spectrometers, which currently comprise six different instrument 
types including LTQ-Orbitrap, Orbitrap Velos and Elite, Exactive, Q Exactive, and 
Orbitrap Fusion. 
The LTQ-Orbitrap, Orbitrap Velos, and Orbitrap Elite are hybrid configurations 
where low-resolution linear ion-traps are combined with high-resolution Orbitraps 
analyzers. The Orbitrap Velos was equipped with a novel ion source that replaced 
the previous tube lens with a radiofrequency (RF) driven S-lens, enabling 10-fold 
better ion transmission. Further improvements of the Orbitrap itself were 
implemented in the third generation of hybrid mass spectrometers, the Orbitrap 
Elite. It was equipped with a compact high-field Orbitrap analyzer, where the inner 
diameter of the outer electrode was reduced from 30 to 20 mm, yielding twice the 
resolving power. The Exactive consists only of an Orbitrap analyzer and is mainly 
used for small molecule analysis. In contrast, Q Exactive type instruments are 
additionally equipped with a quadrupole enabling ion selection, isolation and 
fragmentation upstream of the Orbitrap. In this type of instrument, the Orbitrap is the 
only mass analyzer, where MS1 and MS2 scans are always measured with high 
resolution. Due to its simple design and excellent performance, the Q Exactive has 
become an instrument of choice for proteomics in general (Figure 5). It is a benchtop 
mass spectrometer, which is an important step to move MS towards clinical 
applications. Finally, the Orbitrap Fusion (Lumos) is a high end instrument that can 
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perform CID/HCD/ETD, detect intact and fragmented peptides in the ion trap and 
perform multi-stage fragmentation (MS3 and higher), Orbitrap or both. 
 
 
Figure 5 Functional elements in the Q Exactive HF mass spectrometer57. 
 
1.2.10. Acquisition methods 
 
In bottom-up proteomics, three main acquisition strategies are used2. The topN 
method described above is a data dependent acquisition (DDA) strategy that has 
been the mainstay of hypothesis-free shotgun (discovery) proteomics. In contrast, 
targeted proteomics methods is used for acquiring a predefined set of peptides. 
They monitor specific precursor-fragment transitions and come in flavors such as 
single or multiple/parallel reaction monitoring SRM, MRM and PRM. Finally, data 
independent acquisition (DIA) acquisition cycles through relatively large mass 
windows to generate complex MS2 scans that cover all peptide precursors. It is an 
emerging technology that has the advantage of generating comprehensive 
fragment-ion maps. 
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In more detail, a typical, top10 acquisition cycle on the Q Exactive HF instrument 
consists of one MS1 scan followed by 10 MS2 scans and takes roughly one second. 
Spectra are collected in the Orbitrap mass analyzer and the top 10 most intense 
ions of the full scan are selected by the quadrupole with an isolation width chosen 
to balance ion transmission and specific fragmentation of the intended precursor 
(typically 1.4 m/z on our current instruments) for subsequent fragmentation in the 
HCD collision cell. Likewise, an optimal fragmentation energy is chosen to yield 
good fragment coverage and high MS2 identification rate (‘normalized collision 
energy’ of 27% on a Q Exactive HF instrument)58. To prevent the re-fragmentation 
of peptides, precursors with the same mass are excluded from resequencing for 
about 30 sec, more than the time taken for a typical peptide to elute from the HPLC 
column. The resulting spectra contain information about the m/z values, retention 
times and ion intensities for all the detected fragment ions. They are submitted to 
software packages like MaxQuant59 to extract peptide information for identification 
and quantification (see below). Due to the semi-stochastic selection of precursors 
at the MS1 level in DDA, some precursors are not fragmented in every LC-MS/MS 
runs, leading to missing values, which can lead to problems in downstream analysis. 
This occurs mainly for low abundance peptides. To overcome this challenge, 
MaxQuant has a ‘match between runs’ feature which transfers identifications from 
runs where a peptide was sequenced to another where it was not, based on the m/z 
ratios and retention times of the MS1 features60,61. This way, if in a given LC-MS run 
the required MS2 scan is not present or not interpretable, it can be transferred from 
another LC-MS run. This matching strategy is particularly powerful in challenging, 
high-dynamic range proteomics such as plasma62 and the heart muscle (Article 6). 
A more recent acquisition method, termed ‘BoxCar’ further boosts the depth of 
primarily high dynamic range proteomes63. The capacity of the C-trap is limited to 
about one million charges54,64, therefore high abundant ions often fill the C-trap in a 
very short time (<1 ms), effectively displacing low abundance peptides. This 1 ms 
corresponds to less than 1% of the transient time for a high resolution mass 
spectrum (128 ms for 60,000 resolution). These observations imply that 99% of the 
generated ions are not used for mass analysis at the MS1 level. BoxCar increases 
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the dynamic range at the MS1 level by dividing the mass range into many segments, 
which are sequentially filled (typically 30 segments in three separate MS1 scans). 
This maximizes the usage of the incoming ion current by giving low abundant ions 
longer injection times compared to high abundant ions. Consequently, fewer 
missing values are observed using BoxCar, which makes optimal use of matching 
identifications from a library at the MS1 level. In the heart atlas (Article 6) we applied 
BoxCar for the first time in the context of a translational study. 
There are several implementations of DIA65, the most well-known of which is 
‘sequential window acquisition of all theoretical mass spectra’ (SWATH), in which 
ranges of precursors (typically 25 Da windows) are selected and fragmented 
together66. This results in complex fragment ion mixtures deriving from different 
precursors. Until recently, SWATH was limited to the detection of only the most 
abundant part of the proteome, for instance 2,000 proteins in cancer tissues67. 
Recent developments have made DIA acquisitions much more competitive. They 
have recently been shown to largely eliminate the missing value problem and 
reproducibly quantify protein abundances, reaching CVs down to 5% in technical 
triplicates68. However, DIA generally relies on information from pre-existing high-
quality spectral libraries. Both DDA and DIA are discovery-oriented and unbiased. 
The third bottom-up acquisition mode is targeted proteomics (SRM/MRM/PRM69,70) 
whose goal is to detect a limited set of peptides with high reproducibility and 
specificity. Targeted measurements require the creation of an inclusion list of 
predetermined transitions (precursor/product ion pairs) and peptides. SRM and 
MRM measurements are performed on triple quadrupole instruments (QQQ), where 
the first selects the ions, the second contains the ions during fragmentation, and the 
third quadrupole detects one (SRM) or more (MRM) product ions. MRM can yield 
very reproducible and sensitive but suffers from limited specificity as a results of the 
poor resolution and in practice is restricted to monitoring a small number of peptides. 
In contrast, PRM is performed on a quadrupole-Orbitrap mass spectrometer offering 
a clear advantage in terms of the high resolution, trapping, and high-throughput 
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capabilities of this instrument. In article 3, we describe a histone PTM inclusion list 
for targeted PRM measurements using the Skyline software for quantitation. 
 
1.2.11. Protein identification and quantification 
 
A key step in the shotgun proteomic workflow is the identification of proteins, which 
relies on the interpretation of MS2 product ion spectra. Each peptide will generate 
specific peptide fragment ions forming N-terminal (b-ions) or C-terminal (y-ions) 
sequence ladders. With a complete series, the entire peptide sequence can be 
assigned (‘de novo’ sequencing) (Figure 6). More commonly, the series are 
incomplete and identification of spectra is carried out by database searches using 
peptide search engines, such as Mascot or Andromeda71,72. Both are based on 
matching experimental to theoretical MS2 spectra that have been obtained through 
in silico digestion of all proteins of a given organism73. To control for false positive 
hits (i.e. spectra that are assigned the wrong peptide), spectra are matched to a 
database that includes each peptide in the in silico digest in both the true amino acid 
order and reverse order. The resulting numbers of hits to the reversed database can 
be used to define a false discovery rate (FDR), which is usually set to less than 1%. 
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Figure 6 De novo interpretation of an MS/MS spectrum acquired in an ion trap, assigning 
the sequence IEISELNR74. 
Next, peptide identifications are assembled into protein identifications, which is also 
FDR controlled. Some peptide sequences are not unique to a specific protein, such 
as those that match several protein isoforms. Following Occam’s razor principle – 
that the simplest explanation is the most likely – they can be assigned to the protein 
sequence that already contains the most unique peptides and are then called ‘razor 
peptides’. 
Protein identification is only a first step in gaining insight into the complexity of a 
biological system. Proteins span an abundance range of more than six orders of 
magnitude (or even more than ten orders in plasma and muscle), which already 
makes it clear that quantitative information about protein abundance changes is 
indispensable in the study of biological systems. Quantitative information can be 
obtained in a ‘relative’ or ‘absolute’ fashion, where protein abundances are either 
compared to each other or their concentration or copy number is determined. 
Absolute quantities can be estimated indirectly or – potentially most accurately – 
measured by comparison to a spiked-in absolute reference. Many quantification 
strategies have been developed (Figure 7) and at the highest level they can be 
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categorized in those using stable isotopes and those relying on ‘label-free’ 
approaches. 
 
1.2.12. Label- and label free-based quantification 
 
Label-based quantification methods involve the incorporation of stable isotopes 
either metabolically, by supplying labeled compounds, or chemically via conjugation 
of stable isotope tags to peptides or proteins. Introduction of these stable isotopes 
generally do not affect the physical behavior of a given (tagged) peptide in terms of 
elution profiles or physical properties. In-vivo metabolic labeling, most commonly by 
stable isotope labeling by amino acids in cell culture (SILAC), introduces a defined 
mass shift between the samples that can be distinguished at the MS1 level75. For 
example, labeling can be achieved by providing heavy 13C6 15N2-lysine and 13C6 
15N4-arginine (K8R10), which introduces an 8 or 10 Da mass increase for a labeled 
lysine- or arginine-containing tryptic peptide, respectively. SILAC experiments can 
be extended to a triplex format, using ‘medium’ 2H4-lysine and ‘heavy’ 13C6- arginine 
(R6K4). The abundance differences of the proteins are determined from the relative 
intensity of the corresponding heavy and light labeled peptides. In metabolic 
labeling, samples are combined up-front, thus it has the advantage to directly 
correcting for any sample preparation biases at the LC-MS level. However, this 
method suffers from reduced peptide identification because of increased spectral 
complexity at the MS1 level, and it is only applicable to cellular and certain 
mammalian systems, such as the SILAC mouse or fly or plants76–79. Much smaller 
changes (in the mDa range) can be introduced in a SILAC variant called Neutron-
encoded (NeuCode) SILAC labeled samples80. Other extensions of the classical 
SILAC approach, include spiking in entire labeled proteomes (mix of cell lines 
(super-SILAC)81, or SILAC-labeled protein epitope signature tags (PrESTs)82. For 
absolute quantification, protein standard absolute quantification (PSAQ)83, or 
peptides (AQUA peptides)) can also be used as internal standards, but this is limited 
to a moderate number of proteins of interest. In the SILAC-PrEST approach, a 
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known quantity of recombinant heavy-labeled standards is added into each of the 
experimental samples, which then are processed and analyzed together. Peptide 
ratios between samples and the heavy-spike-in standard are readily calculated and 
absolute quantification of up to 40 proteins of interest has been reported82. 
Other methods for absolute quantification include the estimation of copy numbers 
per cell using the ‘proteomic ruler’ approach, which relies upon the fixed relationship 
between histones and DNA allowing MS-signals to be placed on an absolute scale84. 
Chemical labeling is a strategy to incorporate stable isotopes, and can be used for 
any sample, including primary tissues and body fluids. Here, labeling is generally 
performed by derivatization at the peptide level. One such method is dimethyl 
labeling that has three available channels due to conversion of each primary amine 
to a secondary amine with isotope labeled formaldehyde85. More popular strategies 
for chemical labeling, simultaneously overcome the spectral complexity problem, 
and include isobaric tags for relative and absolute quantification (iTRAQ, 8 
channels)86 and tandem mass tags (TMT, 11 channels)87. These tags are composed 
of three main functional parts, an amine-reactive group for attaching the label to the 
N-terminal amine groups of lysine residues of the amino terminus of the peptides, a 
reporter ion group for relative quantification, and a mass balancer group so that 
peptides share the same MS1 mass. These tags offer greater multiplexing without 
increasing spectral complexity and can decrease measurement time by the degree 
of multiplexing. The MS2 spectra obtained from fragmentation of isobarically labeled 
peptides contain two types of product ion peaks: reporter ion peaks that reflect the 
abundance of the input material in each channel, and the peptide fragment ion 
peaks that permit identification. While TMT-based multiplexing greatly increases the 
overall throughput of sample measurements, it suffers from ‘ratio compression’, 
where the actual ratio between channels are underestimated due to reporter ions 
from co-isolated and co-fragmented ‘contaminating peptides’88,89. This phenomenon 
is a result of the relatively low resolution of quadrupole isolation of precursors. In 
the low-mass reporter ion region of the fragmentation spectra, the target peptide 
and the contaminating peptide give rise to identical reporter ions, ‘compressing’ the 
actual ratios resulting in an underestimation of peptide abundance differences. To 
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partially overcome this challenge, the isolation window can be narrowed, but 
requires high performance quadrupoles90. Alternatively, the tag-containing 
fragments of the precursor can be further isolated and fragmented but this requires 
mass spectrometer capable of MS3, albeit at the expense of sequencing speed and 
proteome coverage. Isobaric tags generally also generate an ion species containing 
the intact peptides and the tag without the low mass reporter ion91. Quantification 
using these ‘complementary reporter ions’ does not suffer from ratio compression92. 
With future improvements in tag chemistry and instruments, this strategy holds great 
promise for accurate measurement of proteins changes at high throughput. 
 
Figure 7 Different MS-based quantification strategies. A) SILAC based quantification is 
performed at the MS1 level. B) TMT-based quantification can currently be multiplexed to 
11-fold and here quantification is performed at the MS2 level and based on reporter ions. 
C) Label free quantification can be done at the MS1 or MS2 level. In all strategies, the 
peptide identification is performed after peptide fragmentation at the MS2 level. 
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As label free quantification (LFQ) completely omits additional chemical reagents and 
procedures it is by its nature the simplest and most economical approach. Early 
label-free quantification methods rely the fact that the number of peptide spectrum 
matches tends to correlate with protein abundance, and included ‘spectral counting’ 
and the emPAI method93. More recent methods are greatly superior as they directly 
quantify the intensity of the precursor ions by measuring the area underneath the 
extrapolated curve of the precursor intensities in MS1 scans over the LC peak. In 
combination with sophisticated algorithms, such as MaxLFQ this has been shown 
to yield very accurate quantification, especially on high-resolution instruments. 
Since sample preparation and measurement is performed for each sample 
individually, the reproducibility of LFQ is usually worse than labeled-based 
quantification. To overcome this, our group has developed automated sample 
preparation workflows24,62, which together with MaxLFQ largely eliminate potential 
technical variations introduced during sample preparation and MS measurements. 
LFQ, together with robust and streamlined sample preparation workflows and the 
unlimited number of samples that can be compared, has become a popular 
approach. 
 
1.2.12. Nearly complete proteomes 
 
Significant improvements of all steps of today’s MS workflow, encompassing sample 
preparation to measurement and subsequent bioinformatics analysis, have enabled 
the characterization of nearly complete proteomes7,46,94. More than 10,000 proteins 
can be routinely quantified in cell lines, model organisms and even in very 
challenging tissues, such as heart muscle (Article 6). In a recent study7, Notably the 
recent report of a very deep HeLa proteome also showed that the depth of 
proteomics is now on par with RNA-based methods. The authors combined 
extensive high pH reversed-phase fractionation with short LC-MS/MS gradients, 
resulting in a sufficient number of peptide precursors to saturate the sequencing 
speed of modern MS instruments. Using the aforementioned method, more than 
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12,000 proteins (and >14,000 protein isoforms) were catalogued. Moreover, more 
than 7,000 acetylation sites and 10,000 phosphorylation sites were identified and 
quantified, even without any enrichment. Other proteomic studies have explored key 
regulatory mechanisms at a large scale. For example, temporal changes in 
phosphorylation have been investigated, on both long and short timescales30,95,96. 
‘Organellar proteomics’ can also be employed to determine subcellular localization 
on a system-wide scale97,98, and more recently this was done in a dynamic fashion 
to monitor subcellular localization changes99. At higher resolution, interaction 
partners of specific proteins can be uncovered through immunoprecipitation 
experiments followed by MS. Global application of interactomics has resulted in draft 
maps of the human interactome, an extensive network analysis of thousands of 
proteins100,101. Finally, the integration of measurements from several types of human 
tissue proteomes combined with data generated by the community resulted in two 
‘drafts of the human proteome’102,103. These drafts, however, were very incomplete; 
to illustrate this, our human heart atlas identified three times as many cardiac 
proteins – mostly of low abundance. Furthermore, the total number of proteins 
identified in these draft proteome studies is overestimated since their FDR is 
unusually high104. Nevertheless, these human proteome drafts illustrate the desire 
of the community to determine the complete proteome to better understand the 
complex protein composition in the human body. 
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2. The cancer proteome at the nuclear, cellular and tissue 
level 
 
‘Cancer begins and ends with people’ – June Goodfield 
2.1. Cancer 
 
The emperor of all maladies105, cancer, accounts for approximately nine million 
deaths worldwide annually106. About one in three women and one in two men will 
develop cancer during their lifetimes. In some regions, cancer is even predicted to 
surpass cardiovascular diseases. Cancer is the Latin word for Crab, this association 
was penned by Hippocrates around 400 B.C. most likely because of its finger-like 
projections that are reminiscent of the outline of a crab. Malignant cell growth, which 
is dictated by ‘hallmarks of cancer’, is the fundamental feature that is shared 
between these cells107,108. Cancer incidence has risen significantly over the last 
decades. With longer life expectancies, it has become evident that the risk of 
developing cancer correlates with age. For instance, a 30-year-old woman has a 
one in 400 annual risk to develop breast cancer compared to one in nine for a 
seventy-year-old. Our capabilities to detect cancer at early stages have much 
increased in the last century. Introduction of mammography screening in the early 
1980s, was followed by higher reported breast cancer incidences109. Changes in 
modern life styles have also influenced cancer statistics. For example, lung cancer 
incidence has exploded in the 1950s, correlating with the increase of cigarette 
smoking and this cancer still remains the most common cause of cancer death. 
There is also a significant link between obesity and cancer, as approximately one in 
five cancer deaths are associated with obesity110. 
Many cancer subtypes, in particular rare cancers, remain poorly understood and 
conventional chemotherapeutic treatments are still associated with life-threatening 
toxic side effects111. This is primarily due to a lack of specificity towards cancer cells 
or the known or suspected molecular drivers. Only a small percentage of patients 
will benefit from the treatment, and the number of patients that need to be treated 
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before one of them actually benefits from the treatment (NNT) remains strikingly 
high (>40 in prostate cancer, for example112). Chemotherapy, specifically, has 
serious side effects, to which a substantial percentage will succumb. These 
numbers underscore the urgent need to develop more effective medicines, and 
uncover predictive biomarkers that will help to stratify patients and target those most 
likely to respond to a specific therapy. 
 
2.2. Personalized cancer medicine 
 
The concept of precision or personalized medicine was already born thousands of 
years ago when Hippocrates said, ‘It’s far more important to know what person the 
disease has than what disease the person has’. Today, the goal of personalized 
medicine is to individualize clinical decisions, thus distinguishing patients that are 
most likely to respond and benefit from a given treatment from those who will only 
suffer from detrimental side effects without benefit while still incurring health care 
costs. The sequencing of the human genome and ongoing rapid technological 
developments have set in motion the transformation of personalized medicine from 
an idea to practice. For a small subset of patients, this has already become reality. 
A pioneering study showed that imatinib (Gleevec, Norvartis)113 specifically inhibits 
the fusion protein BCR-ABL, which drives chronic myeloid leukemia. This drug led 
to patient survival in about 90% of patients114. Another example is the monoclonal 
antibody Trastuzumab (Herceptin, Genentech), prescribed for HER2-positive breast 
cancers where patients show improved survival115. Monoclonal antibodies targeting 
EGFR have also shown clinical efficacy, for instance in patients with EGFR-
expressing metastatic colon cancer116. 
While next generation sequencing has driven the field since the turn of the 
millennium, and allowed the molecular profiling of thousands of tumors in different 
cancer types1, it has become evident that the development and complexity of cancer 
does not lie in genetic changes alone. Clearly, epigenetic changes, protein 
expression alterations, and aberrant PTMs play essential roles in the development 
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of cancer. Thus, the use of MS-based proteomics holds great promise to unmask 
the cause and highlight potential therapeutic targets in the next generation of 
treatment.  
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2.3. Nuclear level: The epigenetic landscape in oncology 
 
2.3.1. Epigenetics 
 
The nucleus is at the heart of each cell. Genetic information is stored in the form of 
chromatin, which consists of DNA that is tightly wrapped around octameric histone 
proteins (H3, H4, H2A, and H2B), forming nucleosomes. Modifications at the histone 
level can result in changes in gene expression even without alterations in the DNA 
sequence. These ‘epigenetic changes’ are frequently observed in tumors117–120. 
DNA itself can also be modified, resulting in hyper- or hypometylation at the global 
or local DNA level at certain CpG islands of promoter regions, and these are 
commonly altered epigenetic patterns of cancers. 
Histones contain lysine-rich N-terminal tails whose positive charges interact with the 
negatively charged phosphate backbone of the DNA. The structure of this 
nucleosome complex can be modified by multiple PTMs, including acetylation and 
methylation of histone tails that influence gene expression. In general, tightly packed 
chromatin (heterochromatin) is associated with histone methylation and gene-
silencing, whereas open chromatin (euchromatin) is associated with histone 
acetylation and gene-expression. These acetyl and methyl marks present another 
regulatory mechanism of the epigenetic machinery. Proteins that catalyze (‘writers’), 
recognize (‘readers’) or reverse (‘erasers’) the transfer of histone marks (Figure 8) 
are frequently altered in tumors. 
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Figure 8  The main epigenetic regulators can be classified into three categories: 
epigenetic ‘writers’ (enzymes that deposit covalent modifications on histone tails), ‘readers’ 
(proteins that bind to histone modifications), and ‘erasers’ (enzymes that catalyze the 
removal of modifications on histone tails) 
 
2.3.2. Contributions of MS-based proteomics to epigenetics 
 
MS-based proteomics has become an invaluable method to study epigenetic 
regulation in an unbiased way. While conventional proteomic workflows are not 
suitable for lysine-rich and hydrophilic histone tails, specialized protocols have been 
developed and are in routine use28,29,121. For bottom-up histone tail analysis, 
optimizations include the propionylation of histones to increase sequence coverage 
and peptide-level phenyl isocyanate labeling to improve HPLC retention and the 
detectability of hydrophilic peptides. For the more complete analysis of 
combinatorial histone PTMs, relatively long amino acid sequences (~50-mers) can 
be directly analyzed via ‘middle-down’ proteomics122. To this end, intact N-terminal 
tails are generated by Glu-C or Asp-N mediated digestion of histone H3 or H4, 
respectively. Middle-down approaches, however, still suffers from relatively poor 
sensitivity in comparison to bottom-up workflows and the interpretation of MS2 
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spectra remains computationally intensive and laborious. Adding ion mobility 
separation to MS-based strategy holds great promise for the analysis of challenging 
histone PTM combinations, such as H4 acetylations, which are chromatographically 
almost indistinguishable123,124. Here, ions are separated by their mobility in a low 
pressure gas under the influence of an electric field. This mobility is determined by 
their size-to-charge ratio (collisional cross section). Together, these diverse MS-
based workflows have enabled the accurate description of histone variants such as 
the nearly identical histone variants H3.1 and H3.3. Multiple novel histone marks, 
such as O-GlyNAc, butyrylation, crotonylation, citrullination, and formylation have 
been described on histones125. The more well described marks, including histone 
acetylation and methylation can now be reproducibly and accurately quantified29. In 
addition to these histone marks, we show in article 3 that histone butyrylation 
alterations can be quantified. Other examples of successful application of MS-based 
workflows to epigenetics include the discovery of the effects of the histone 
demethylase KDM5 inhibitors121, the role of macroH2A in melanoma126, and 
quantification of histone PTM dynamics in cellular systems127. In addition, cross-
talks between different sites and types of histone PTMs have been described and 
histone marks triggering the recruitment of specific epigenetic ‘writer’128,129. 
 
2.3.3. The histone methyltransferase enhancer of zeste   
homolog 2 
 
The epigenetic writer enhancer of zeste homolog 2 (EZH2) is the driving catalytic 
subunit of the polycomb repressive complex 2 (PRC2) (Figure 9). As a 
methyltransferase, it tri-methylates histone 3 on lysine 27 (H3K27me3), a 
transcriptionally repressive epigenetic mark that silences gene expression. It has 
been found to inactivate multiple tumor suppressor genes, such as CDKN1C130,131. 
In a second mode of action, EZH2 promotes cell proliferation via STAT3 
methylation132 or BRAC1 inactivation133. EZH2 is overexpressed in multiple human 
cancers, including lymphoma and its inhibition has been shown to induce apoptosis 
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of cancer cells134–136. Adding to these findings, we show in article 2 that cell cycle 
regulators are down-regulated at the proteomic level following H3K27me3 
demethylation in lymphoma cells. 
 
 
Figure 9 Model of the role of EZH2 in cell cycle regulation. By repressing transcription as a 
member of the PRC2 complex (left panel), EZH2 enhances the expression of cell cycle 
regulators indirectly by repressing associated tumor suppressors.EZH2 can also act as a 
direct activator of cell proliferation following phosphorylation (right panel). In its 
phosphorylated form, EZH2 activates STAT3 via methylation, which subsequently induces 
cell proliferation. EZH2 can also phosphorylate BRAC1 via Akt1 interaction, resulting in cell 
cycle activation as well (Figure from article 2). 
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2.3.4. Histone demethylases 
 
Histone demethylases are epigenetic erasers and come in two main varieties, (i) 
jumonji (JmjC) domain-containing demethylases, and (ii) the lysine-specific 
demethylase (KDM1A/LSD1) family. Both classes play important roles in cancer137. 
 
2.3.4.1. JmjC domain-containing histone demethylases 
 
JmjC domain-containing histone demethylases are the largest class of histone 
demethylases and employ an oxidative mechanisms that is Fe2+ and alpha–
ketoglutarate (α-KG) dependent. They can remove all three histone lysine 
methylation states, unlike the LSD1 family, which can only remove mono- and 
dimethyl lysine modifications. In the context of glioblastoma, which is among the 
deadliest human cancers, we and others have shown that α-KG-dependent 
demethylases are inhibited in glioblastoma cell line models that harbor somatic 
isocitrate dehydrogenase 1 (IDH1) mutations (Article 3)138. Clinically, there are 
primary glioblastomas (which rapidly progress and develop de novo) and secondary 
glioblastoma (which progress slowly after initially presenting as low-grade gliomas. 
Interestingly, the majority of secondary (>70%) but rarely primary glioblastomas 
harbor IDH1 mutations, involving Arg132 in nearly all cases139. IDH enzymes are 
key regulators of the TCA cycle by converting isocitrate into α-KG. The monoallelic 
IDH mutation, however, generates an enzyme with neomorphic ability to convert α-
KG into 2-hydroxyglutarate (2-HG). As a result, the oncometabolite 2-HG 
accumulates to very high levels in IDH mutant tumors and inhibits α-KG dependent 
histone demethylases and DNA demethylases140,141 (Figure 10). This subsequently 
results in increased global DNA hyper methylation138 and down-regulation part of 
the proteome as shown in article 3. These observations suggest that different 
therapeutic interventions should be used in primary versus secondary glioblastoma. 
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Figure 10 Mechanism by which IDH mutations lead to alterations at the epigenetic and 
gene expression levels (Figure from article 3). 
 
2.3.4.2. Lysine-specific histone demethylases 
 
The lysine-specific histone demethylase 1 (LSD1, also known as KDM1A) is a flavin 
adenine dinucleotide (FAD)-dependent amine oxidase. LSD1 was the first histone 
demethylase to be discovered142. Acting as an epigenetic eraser, it demethylates 
mono- and di-methylated lysines (H3K4 and H3K9), thereby acting as a coactivator 
or corepressor, depending on the context143. LSD1 has emerged as an interesting 
therapeutic target because it is overexpressed in many cancer types, including lung 
cancer144,145. We also found that LSD1 is upregulated in the extremely rare and little 
studied urachus carcinoma cancer (Article 7). Furthermore, inhibition of LSD1 
inhibits tumors that gave rise to the development of multiple anti-LSD1 drugs that 
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are currently in clinical trials145–147. Tranylcypromine, an FDA-approved 
antidepressant148, arose particular interest in the context of cancer treatment 
because it revealed a strong LSD1-specific inhibitor side effect149,150. 
Tranylcypromine and derivates of this drug showed clinical efficacy for several 
indications, including the treatment of AML and are currently in clinical trials151. 
  
36 
 
2.4. Cellular level: The phosphorylation-based signaling 
landscape in oncology 
 
2.4.1. Phosphorylation 
 
Phosphorylation is the replacement of the neutral OH of the side chains of amino 
acids serine, threonine, or tyrosine by the negatively charge phosphoryl group 
(PO3−) and is subsequently converted to phosphate PO42- (Figure 11). The negative 
charge can induce conformational changes, modulate protein activity, and mediate 
or inhibit interaction with other proteins by providing a docking site. Kinases and 
phosphatases are enzymes that covalently modify proteins by either adding or 
removing phosphate groups. More than 500 putative protein kinase genes have 
been described, constituting about 2% of all human genes, that can be classified in 
a kinome tree152. 
 
Figure 11 Phosphorylation and dephosphorylation mechanisms. The phosphorylation of 
protein residues (serine, threonine or tyrosine) is catalyzed by protein kinases. The reaction 
of dephosphorylation is mediated by protein phosphatases153. 
 
Cellular phosphorylation signaling networks are complex interaction systems that 
connect sequence-specific kinases and/or phosphatases to their respective target 
proteins. A typical phosphorylation-signaling cascade starts with the stimulation of 
RTKs via growth factors. This leads to their phosphorylation and activates a 
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phosphorylation cascade via adaptor proteins, for instance those containing a Src 
homology 2 (SH2) domain that specifically bind phosphorylated tyrosines. 
 
2.4.2. The MAPK and PI3K pathways 
 
The RAS-RAF-MEK-ERK (MAPK) and PI3K-AKT-mTOR (PI3K) pathways (Figure 
12) were discovered about 30 years ago and are evolutionary conserved kinase 
families that control key cellular mechanisms, such as cell proliferation, survival, 
metabolism, and motility upon extracellular stimuli154–158. 
 
Figure 12 The MAPK and PI3K pathways are activated in multiple cancers driving cell 
proliferation, adapted from article 3. 
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When the master regulator RAS is activated it mediates a phosphorylation cascade 
including key kinases, such as mitogen-activated protein kinase (MAPK, also known 
as extracellular signal regulated kinase (ERK)) and phosphoinositide 3-kinase 
(PI3K). MAPK functions as the major effector of the RAS oncoprotein, which is a 
member of the large family of GTPases. The RAS oncogenes were initially 
discovered in murine sarcoma viruses159,160 and three human RAS genes have been 
described to date (H-RAS, N-RAS and K-RAS). They are anchored to the plasma 
membrane and function as molecular switches. Adaptors, such as the growth factor 
receptor bound protein 2 (Grb2) and the nucleotide exchange factor son of 
sevenless (SOS) enable the conversion of guanosine diphosphate (GDP) bound to 
RAS to guanosine triphosphate (GTP) in the cytoplasm161. This exchange allows 
the subsequent activation of RAF, MEK and MAPK. In its inactive form, MAPK 
presents a catalytic site that is blocked by a segment of amino acids, termed the lip. 
The binding of MEK to MAPK destabilizes the lip structure, leading to the exposure 
of a tyrosine and threonine that are subsequently phosphorylated by MEK. This 
results in conformational changes and enables the binding of ATP in the catalytic 
site of MAPK and its dimerization. Exclusively in this dimerized form, MAPK can be 
translocated to the nucleus where it regulates the activation of numerous 
transcription factors, such as MYC. 
PI3K phosphorylates inositol membrane lipids to generate phosphatidylinositol 
3,4,5-trisphosphate (PIP3) which in turn modulates the activity of intracellular 
protein effectors. PIP3 recruits pleckstrin homology (PH) domain containing proteins 
to the membrane, such as AKT1 and PDK1, which subsequently activate signaling 
cascades involved in cell growth and proliferation. Both pathways actively cross-
talk. They can negatively regulate each other’s activity, a phenomenon that is 
frequently observed when one of the two pathways is actively inhibited with a drug. 
For instance, MEK inhibition leads to the EGF-mediated hyperactivation of AKT162. 
Both pathways can also cross activate each other by regulating common down-
stream nodes, such as the TSC1/2 complex (Figure 12). 
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The MAPK and PI3K pathways are frequently deregulated in cancer because they 
play central roles in the control of cell proliferation, apoptotic pathways, oncogenic 
kinase signaling, and transcriptional regulation. Recent large-scale genomic 
sequencing initiatives of thousands of tumors through the TCGA consortium made 
the significance of both pathways very apparent on a global scale1. This uncovered 
BRAF, KRAS, PIK3CA and PTEN as the most frequently mutated genes in cancer. 
In endometrial carcinoma, for example, PIK3CA showed somatic mutations in 53% 
of 240 tumors. Similarly, KRAS is the most frequently altered signaling node of the 
MAPK pathway, being mutated in about 40% of colorectal carcinomas163 and BRAF 
mutations were found in 60% of thyroid carcinomas164. These key regulators show 
the most significant ‘mutation hot spots’ in cancer165, defined as the enriched 
occurrence of specific point mutations within the gene and characteristic for its 
cancer driving function. The most frequent hot spots are V600E in BRAF, and 
E545K in the helical and H1047R in the kinase domains of PIK3CA. 
 
2.4.3. Development of kinase inhibitors 
 
Protein kinases have become a major class of drug targets and today about 37 
kinase inhibitors are FDA approved with an additional 250 in clinical trials166. Among 
those, small molecules targeting the key nodes of the MAPK and PI3K pathways 
have been most intensely pursued for cancer treatment. While some, such as RAS 
cannot be directly targeted yet (#YetToBeDrugged)167, others have advanced into 
the preclinical stage as validated targets. Specific MAPK and PI3K inhibitors include 
cobimetinib (GDC-0973), pictilisib (GDC-0941), and taselisib (GDC-0032) which are 
used in articles 3, 4 and 5. The oral, potent, and selective MEK inhibitor cobimetinib 
has been approved for the treatment of melanoma in combination with BRAF 
inhibitors168,169. Pictilisib, is an oral, highly specific, ATP-competitive small-molecule 
class I pan-PI3K inhibitor170. It has demonstrated significant antitumor activity in a 
wide array of cancer models in preclinical studies171–173. Similarly, taselisib is an 
oral, potent and selective inhibitor of mutant PIK3CA. It is currently in clinical phases 
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I, II and III for the treatment of advanced solid tumors, lung and breast cancer, 
respectively174–176. 
Besides kinase inhibitors, other anticancer strategies use targeted protein 
degradation mechanisms, such as the proteolysis targeting chimeras (PROTAC) 
technology, where small molecules simultaneously bind a target protein and a 
ubiquitin ligase, enabling its ubiquitination and degradation in a generic way177,178. 
While targeted therapies that block signaling through the MAPK and PI3K pathways 
have shown clinical efficacy in several tumor types, the underlying signaling 
phosphorylation cascades often remain poorly understood. The core signaling axes 
of the two pathways span intricate networks, in which only a few substrates and 
connections are well characterized so far. 
 
2.4.4. MS-based phosphoproteomics of the MAPK and PI3K 
pathways 
 
Studying the dynamics of signal transduction networks in response to EGF 
stimulation revealed that different phosphorylation sites of the same protein often 
show distinct kinetics8. Hence, accurate modelling of a signaling pathway requires 
treating it not only as a network of proteins but also as a network of interconnected 
phosphorylation sites. Modifying specific nodes in this network by altering the 
activities of associated protein kinases or phosphatases, may significantly influence 
the entire signaling web and lead to unexpected effects. Only a few studies have 
attempted to explore the global spectrum of phosphorylation signaling downstream 
of the pivotal regulators of the MAPK or PI3K pathways179–182. These efforts 
demonstrated the ability of MS-based proteomics to identify and quantify thousands 
of phosphorylation sites and explore perturbed signaling webs. While these studies 
primarily focused on the signal transduction through a specific protein kinase under 
fixed conditions, in articles 4 and 5 we compared the regulation of 
phosphoproteomes by mutating or inhibiting multiple gatekeepers of the most 
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important cancer pathways, and examined the dependence on inhibitor class, 
dosage, cell type, and type of kinase modulation (activation versus inhibition). In 
addition, we studied the impact of dual inhibition, since combinatorial therapies are 
thought to be superior to single agent treatment. This revealed interesting and 
previously unknown effects on feedback mechanisms. In the clinic, the efficacy of 
combined therapies, remains to be determined183. MS-based analyses of 
convergence, crosstalk, and feedback associated phosphorylation patterns are 
poised to provide important scientific insights into the optimal uses of combination 
strategies to effectively block oncogenic pathways and overcome feedback 
mechanisms.  
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2.5.  Tissue level: ‘from bench to bedside’ 
 
2.5.1. Current cancer diagnosis in clinical practice 
 
In a clinical context, blood sampling and tissue biopsies are the two most common 
means of biological sample collection. Today, the analysis of blood samples is 
dominated by protein-based clinical laboratory tests using single-protein 
immunoassays184. About 42% of analyses requested by clinicians are based on 
proteins, compared to 35% for small molecules and 17% for cells. It is apparent that 
already today, proteins are the most frequently assayed analytes in clinical routine. 
Although the cancer field is dominated by genetic analyses, there are a number of 
established biomarkers for several common cancers. These were discovered and 
are routinely measured by non-proteomic technologies such as ELISAs. The only 
possible exception was the FDA approved blood test ‘OVA1’, which is approved in 
a narrow indication in the context of ovarian cancer (OvCa). OVA1 relies on a 
multiplexed immunoassay to measure the concentration of five individually non-
specific proteins, including apolipoprotein 1 (APOA1), beta‐2 macroglobulin (B2M), 
serum transferrin (TF), pre‐albumin (ALB), and the known OvCa marker CA-125 
(MUC16)185–188. These proteins, however, are in some cases not detected 
specifically enough using immunoassays and it is debated whether they are 
sufficiently specific to OvCa186,189,190. Of note, using high pH reversed-phase 
fractionation and state of the art MS we can easily identify all OVA1 protein 
members with high accuracy in only 1 µl of serum from an OvCa patient (Figure 13). 
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Figure 13 Protein abundance rank in OvCa serum. The five proteins used in the OVA1 test 
are highlighted in red (Data generated by the author). 
For the detection and monitoring of the progression of prostate cancer, prostate-
specific antigen (PSA) levels - a protein produced exclusively by normal and 
malignant prostate gland cells - are measured in the blood. PSA levels above 4 
ng/ml are usually followed by a prostate biopsy and the higher the PSA levels, the 
higher the risk of diagnosing prostate cancer in the biopsy. Higher PSA levels, 
however, also correlate with benign enlargement of the prostate or infections, 
meaning that these test are not very specific (high false positive rates). 
Tissue samples are generally obtained by needle biopsy or surgical excision and 
are subsequently analyzed by diagnostic pathology using hematoxylin and eosin 
(H&E) staining (Figure 14). Hematoxylin colors nuclei of cells in dark purple, 
whereas eosin mainly stains eosinophilic structures, including the cytoplasm, intra- 
and extracellular proteins in pink. Blood cells are stained intensively red. H&E 
staining enables the detection of irregular cell proliferation, stromal infiltration, and 
overall abnormal cellular morphology. In most cases, H&E alone enables the 
diagnosis and grading of cancer. Grading systems based on H&E staining, such as 
the Gleason score for prostate cancer exist since the 1960s and are still routinely 
used as an indicator of how quickly the tumor is likely to grow and spread.  
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Figure 14 H&E stainings of healthy, primary tumor and metastatic tissues. Proliferating cells 
are colored in dark purple, such as the healthy epithelium (left panel) of cancer cells (middle 
and right panels). The prominent pink staining in the middle and right panels is 
representative of prominent stromal infiltration. 
In some cases, further tissue stainings are performed to diagnose a particular 
cancer type/subtype or measure the likelihood of a patient to respond to a particular 
therapeutic treatment. To this end, immunohistochemistry (IHC), which utilizes 
specific antibodies for the detection of proteins in tissue sections is applied. For 
instance, current tissue-based FDA approved protein biomarkers include EGFR for 
the therapy selection of colon cancer or HER2 for breast cancer diagnosis and 
therapy selection. While these blood- and tissue-based tests are routinely used in 
the clinic, they may suffer from lack of specificity, are based on outdated 
technologies in some case, and generally do not enable the early detection of 
cancer development. 
 
2.5.2. Cancer FFPE tissues proteomics 
 
The most frequent method for human tissue preservation is formalin fixation and 
paraffin-embedding (FFPE). It is routinely used in tissue banks due to its long-term 
preservation capabilities, and amenability to downstream IHC. FFPE is an 
economical choice since samples can be stored at room temperature and at great 
density. It is estimated that about half a billion archived FFPE cancer tissue samples 
exist to date191. These immense archives of material in principle present an 
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invaluable resource for studying the underlying molecular mechanisms of cancer, 
testing known biomarkers and uncovering new ones. The main use of FFPE tissues 
in the clinic today is H&E and IHC stainings for the detection of known cancer 
aberrations. It is semiquantitative at best and allows the evaluation of only a few 
targets at a time. FFPE cohorts have been challenging to use in gene expression 
studies due to the difficulty in isolating nucleic acids, often resulting in samples with 
poor RNA quality that are not usable for next generation sequencing192. This was 
also observed in article 7, where RNA sequencing could not be performed because 
most of the RNA was degraded after extraction from FFPE and even from fresh 
frozen cancer tissue. Proteins are more stable than RNA or DNA, therefore protein 
profiling in high-throughput platforms, in principle holds great promise for uncovering 
new biomarkers and improving prognostic and predictive power for clinicians. 
Taking advantage of the stability and ease-of-handling of proteins, protein extraction 
from FFPE material is possible in a robust manner for MS-based analysis. 
Proteomic analysis of almost 30-year old FFPE tissues have been carried out 
successfully193 and the comparison of FFPE to fresh tissues did not reveal major 
quantitative or qualitative differences at the protein or PTM level194. We have 
developed techniques to reverse the cross-links induced upon fixation to ensure 
deep and quantitative proteome profiling to a depth of 10,000 proteins in colorectal 
cancer tissues195–197. Our group has also shown that a combination of tissue 
proteomics and machine-learning classified patients with diffuse large B-cell 
lymphoma depending on the cell of origin198. To enable a more streamlined analysis 
of FFPE samples, we recently demonstrated that in StageTip sample preparation is 
possible in a rapid manner and holds great promise for future applications in the 
clinic (Article 7). Regarding the sample collection and processing, MS-based tissue 
analysis can be performed on whole, marco- or micro-dissected tissues. Currently, 
the majority of large-scale tissue studies are based on whole-tissue specimens, and 
thus contain a mix of heterogeneous tumor cells, their respective tissue 
microenvironment (stroma), and most likely some non-cancer cells. The stroma, 
composed mainly of fibroblasts, immune and endothelial cells has been shown to 
play driving roles during all phases of tumorigenesis and can influence therapy and 
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patient outcome199–201. Laser-capture microdissection (LCM) is particularly powerful 
to isolate homogeneous cell populations for subsequent investigation of proteomic 
differences between tumoral and stromal cells. Procedures in our laboratory can 
now easily quantify several thousands of proteins starting with as little as 10,000 
micro-dissected cells in single MS runs using state of the art MS acquisition 
methods. 
 
2.5.3. In the quest of more reliable and early cancer biomarkers 
using MS-based proteomics 
 
A biomarker is a biological molecule that can be used to define a normal or abnormal 
condition or disease. It may also be used to monitor therapeutic treatment. 
Biomarkers can thus be grouped into prognostic, predictive, and 
pharmacodynamics types202. Prognostic biomarkers provide information about the 
patient’s overall cancer outcome, regardless of therapy. A classical predictive 
biomarker, which estimates the effect of a therapeutic intervention, is the HER2 
protein amplification in breast cancer, which indicates the clinical efficacy of anti-
HER2 antibodies such as Trastuzumab (Herceptin). HER2 is also a prognostic 
biomarker, as HER2+ breast cancers are associated with worse outcome. Similarly, 
EGFR mutated lung tumors have been shown higher sensitivity to erlotinib or 
gefitinib than wild type EGFR lung tumors203. 
Biomarkers can be found at the DNA, RNA, or protein level and several analytical 
platforms have been developed over the years for biomarker discovery. As protein 
reflect the ‘real time’ status of a human body, are actively involved in disease onset 
and are the main targets of currently available cancer therapies, they represent an 
ideal target for biomarker discovery, in addition to the tumor driving DNA mutations. 
Biomarkers for early cancer detection represent one of the most promising 
approaches to fight cancer and improve clinical outcomes for cancer patients204. 
Protein biomarker discovery, however, remains challenging compared to DNA and 
RNA mainly due to the immaturity of the technology and the large dynamic range of 
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proteins found in body fluids and tissues. Recently, our group has developed an 
automated, robust, and highly reproducible workflow to quantify hundreds of plasma 
proteins. Among those there were more than 40 FDA-approved biomarkers62. In a 
similar manner, we are now developing a very rapid and sensitive single run mass 
spectrometric workflow for LCM and marcodissected cancer tissues. The latest 
technological developments now make DIA tissue measurements increasing 
competitive with DDA measurements, with the further attraction of improved 
measurement reproducibility. 
 
2.5.4. Clinical cancer proteomics consortia 
 
Similar to the TCGA project, which sequenced, characterized and catalogued 
cancer-specific alterations for thousands of tumors, the National Cancer Institute’s 
(NCI) clinical proteomic tumor analysis consortium (CPTAC), launched in 2011, 
aims to systematically identify and characterize cancer-relevant proteins and their 
underlying biological pathways. CPTAC also integrates both proteomic and genomic 
data (termed proteogenomics), which are starting to attract interest in the cancer 
community. For example, the proteogenomic characterization of colon and 
colorectal cancer suggested novel proteomic tumor subtypes associated with 
clinical outcome205, similar to previous studies focusing on ovarian206, and breast95 
cancers. Of note, protein levels could not be predicted from genomic or 
transcriptomic data, emphasizing the importance of studying the actual molecular 
actors within a cellular system. Another goal of CPTAC is to enhance precision 
oncology and share data collected with scientists and physicians. Other cancer 
proteomic efforts have been based on DIA SWATH technologies. For instance, the 
MS company SCIEX as well as the Human Proteome Organization (HUPO) 
contribute to the large-scale cancer tissue analyses of multiple tumors with the goal 
of reproducibly identifying and quantifying at least a few thousand proteins. Such 
studies may generate new insights into oncogenesis beyond the genomic and 
transcriptional level.  
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II) Aims of the thesis 
 
The aim of my thesis was to investigate system-wide alterations in cancer at the 
protein level. Starting from cell line models, I moved to translational tissue cancer 
proteomics and showed that MS-based proteomics can be used for therapeutic 
target identification and characterization (Figure 15). 
Similar to the layout above, my journey started in the nucleus of cells, where I 
investigated the epigenetic changes in lymphoma at the biotechnology company 
Genentech Inc. We found that EZH2, which is the most significantly over-expressed 
epigenetic regulator in cancer, is co-regulated with parts of the network driving the 
cell cycle. We also uncovered that IDH1 mutation leads to perturbations of the 
histone code, altering histone tail acetylation and methylation in glioblastoma cell 
line models. 
Zooming out from the nuclear to the cellular level, I analyzed phosphorylation-
signaling changes in primary and secondary glioblastoma cell line models at the 
University of California, San Francisco (UCSF). Here, I focused on the interplay 
between the MAPK and PI3K signaling cascades and showed that dual inhibition is 
superior to single MEK inhibition and that it reverses phosphorylation-signaling 
patterns driven by oncogenic RAS overexpression. We also published an update of 
where the MS-based PTM analysis field stands, with a focus on current enrichment 
strategies and technological advances. 
At the Max Planck Institute (MPI) of Biochemistry, I moved from cellular to 
translational proteomics, investigating human tissues. A major challenge was to 
overcome the high dynamic range of protein concentration in particular tissues, 
which masks the identification of low-abundant proteins. In this context, I gained 
much experience in the course of my exploration of the human heart proteome 
(Article 6). The heart is basically a sophisticated muscle, which is a particularly 
difficult tissue due to the overwhelming contribution of the proteins of the contractile 
apparatus. We combined strategies and technologies such as peptide library 
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matching, the peptide fractionation with the ‘loss-less nano fractionator’, and 
efficient use of the precursor ions with ‘BoxCar’ runs. This combined strategy yielded 
a dramatic increase in the total number of quantified proteins, reaching a depth of 
more than 10,000 proteins in the human heart.  
Based on these technological advances, the final aim of the thesis was to 
demonstrate that MS-based proteomics can be applied to large tissue cohorts and 
that it is possible to gain biologically and medically relevant information. I optimized 
a MS-based proteomic workflow for the rapid screening of clinical tissue samples. 
By applying this workflow to a chemorefractory cancer patient, I uncovered a 
potential therapeutic target at the proteome level. Altogether, my results provide 
unique resources of the identity and quantity of proteins and their (dis)regulation, 
phosphosites and histone PTMs, revealing new insights into oncogenesis in 
different types of cancer. 
 
Figure 15 Overview of my PhD Thesis - A journey through the proteomic landscape 
of cancer. Moving from the nuclear (Genentech Inc.) and cellular (UCSF) levels to clinical 
tissue (MPI) cancer proteomics.  
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III) Publications 
 
Article 1: Mass spectrometry-based detection and assignments of protein 
posttranslational modifications 
Article 2: Bioinformatics analysis of thousands of TCGA tumors to determine the 
involvement of epigenetic regulators in human cancer 
Article 3: Quantitative proteomics reveals fundamental regulatory differences in 
oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) driven astrocytoma 
Article 4: Phosphoproteome analysis of the MAPK pathway reveals previously 
undetected feedback mechanisms 
Article 5: Quantitative phosphoproteomic analysis of the PI3K-regulated signaling 
network 
Article 6: Region and cell-type resolved quantitative proteomic map of the human 
heart  
Article 7: Rapid proteomic workflow for solid tumors reveals LSD1 as a drug target 
in an end stage cancer patient (in preparation)  
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Article 1: Mass spectrometry-based detection and assignment of 
protein posttranslational modifications207 
 
ACS Chemical Biology 
Sophia Doll1,2 and Alma L. Burlingame1 
1Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158-2517 
2Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 
Martinsried, 82152, Germany 
 
Great advances in MS-based proteomics now allow the identification and 
quantitation of thousands of posttranslational modification (PTM) sites in a single 
experiment. Recent developments in chromatography, PTM enrichment strategies, 
and mass spectrometry have vastly increased the known inventory of many protein 
modifications. The classes most actively investigated and discussed in this review 
include phosphorylation, ubiquitination, O-GlcNAcylation, methylation, and 
acetylation. More recently, succinylation, SUMOylation, and citrullination have been 
investigated globally. Characterization of key regulatory roles of PTMs in multiple 
cellular activities, including cancer development, have made PTMs a very attractive 
field of study over the last decade.  
In this review, we provide an update of where the MS-based PTM analysis field 
stands, with a focus on current enrichment strategies and technological advances. 
We discuss affinity purification enrichment strategies based on charge properties, 
and antibody recognition. Furthermore, we review different fragmentation methods 
for high confidence sequence identification and site localization of different PTMs. 
We also highlighted a few examples of the discovery of previously unknown 
biological roles of PTMs. Finally, we addressed the challenge of defining site-
specific functions.  
My review has already been cited approximately 50 times in the last two years. 
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Article 2: Bioinformatics analysis of thousands of TCGA tumors to 
determine the involvement of epigenetic regulators in human 
cancer208 
 
BMC Genomics 
Florian Gnad1*, Sophia Doll2,3, Gerard Manning1, David Arnott2, Zemin Zhang1,4 
1Departments of Bioinformatics and Computational Biology, Genentech, USA.   
2Protein Chemistry, Genentech Inc., South San Francisco, CA 94080, USA.   
3Proteomics and Signal Transduction, Max-Planck-Institute for Biochemistry, Martinsried, Germany.  
4Biodynamic Optical Imaging Center, College of Life Sciences, Peking University, Beijing 100871, 
China. 
 
In this manuscript, we investigated the epigenetic landscape in cancer at a large 
scale. We first aimed to uncover somatic alterations in the epigenetic machinery in 
thousands of tumors from The Cancer Genome Atlas (TCGA) at the genomic level. 
To this end, a classification model that predicts the likelihood of epigenetic regulator 
genes to be an oncogene, tumor suppressor, or neutral gene was trained using 
3,356 tumors from seven cancer types. We found several tumor suppressor genes 
among epigenetic regulators and gene expression and correlation network analysis 
showed that EZH2 was the most significantly over-expressed epigenetic regulator 
in cancer. 
We followed up on this finding at the proteomic level, where we quantified global 
proteomic changes by mass spectrometry after EZH2 inhibition. We treated 
lymphoma cells with the EZH2 inhibitor EPZ-6438 (Tazemetostat) and performed 
quantitative MS-based proteomics on these samples. We found that the repressive 
epigenetic mark H3K27me3 was significantly downregulated and that EZH2 is co-
regulated with parts of the cell cycle network. These results suggest that EZH2 
drives the development of cancer via deregulated cell cycle regulation. 
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Article 3: Quantitative proteomics reveals fundamental regulatory 
differences in oncogenic HRAS and Isocitrate Dehydrogenase 
(IDH1) driven astrocytoma209 
 
Molecular and Cellular Proteomics 
Sophia Doll‡, Anatoly Urisman‡, Juan A. Oses-Prieto‡, David Arnott§, and Alma L. 
Burlingame‡ 
‡Department of Pharmaceutical Chemistry, University of California, San Francisco, 94158–2517 
California 
§Department of Protein Chemistry, Genentech Inc, South San Francisco, 94158 –2517 California 
 
Glioblastoma are the most frequent brain tumors and can be classified into primary 
and secondary glioblastomas. Current therapies combine surgery, radiotherapy, 
chemotherapy, and temozolomide treatment, but less than 5% of the patients 
survive longer than 5 years after diagnosis. Genomic analyses showed that more 
than 70% of secondary glioblastomas harbor IDH1 mutation. The downstream 
effects of IDH1 mutation on the proteome, phosphoproteome, and epigenome in 
glioma, however, remain poorly understood. In this publication, we applied a SILAC 
labeling methodology and high-resolution mass spectrometry to identify the main 
differences between oncogenic HRAS driven cells and mutant IDH1-driven glioma 
cells, mimicking primary and secondary glioblastoma. We found that primary 
glioblastoma cell lines are mainly characterized by the overexpression of the MEK 
and PI3K signaling pathways. Dual inhibition of MEK and PI3K was clearly superior 
to single MEK inhibition in the cell line model; however, clinical efficacy remains to 
be determined. In contrast, secondary glioblastoma cell lines showed epigenetic 
reprograming at the histone code level. Applying a histone hybrid chemical labeling 
method and high-resolution MS, we identified significant histone methylation, 
acetylation, and butyrylation changes. Our results suggest a global transcriptional 
repressive state, consistent with the down-regulation of the proteome, 
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transcriptome, whereas DNA is hyper-methylated and there is an increase in histone 
tri-methylation marks. This work provides a unique resource of the identity of altered 
proteins, phosphosites, and histone PTMs in RAS and IDH1 mutant astrocytoma 
cell lines, revealing new insight into oncogenesis in glioma. I also illustrated the 
January 2017 cover of Molecular and Cellular Proteomics (MCP). 
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Article 4: Phosphoproteome analysis of the MAPK pathway reveals 
previously undetected feedback mechanisms210 
 
Proteomics 
Florian Gnad1, Sophia Doll2, Kyung Song3, Matthew P. Stokes5, John Moffat4, 
Bonnie Liu3, David Arnott2, Jeffrey Wallin3, Lori S. Friedman3, Georgia 
Hatzivassiliou3 and Marcia Belvin3 
1 Department of Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, 
CA, USA  
2 Department of Protein Chemistry, Genentech Inc., South San Francisco, CA, USA  
3 Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA  
4 Department of Biochemical Pharmacology, Genentech Inc., South San Francisco, CA, USA  
5 Cell Signaling Technology Inc., Danvers, MA, USA 
 
The Ras-Raf-MEK-ERK pathway is commonly upregulated in cancer. The 
establishment of targeted MAPK pathway therapies, however, has proven difficult 
as any cancers treated with MEK inhibitors rapidly develop resistance. To decipher 
the underlying cause, it is essential to decrypt the phosphorylation network spanned 
by the MAPK core axis. In this publication, we examined the spectrum of 
phosphorylation signaling downstream of the key nodes of the Ras-Raf-MEK-ERK 
pathway. We employed the label-free based PTMScan method from Cell Signaling 
Technology, and quantified changes in the levels of phosphorylation sites in colon 
cancer cell line HCT116 cells treated with MEK inhibitor cobimetinib (GDC-0973) or 
the ERK inhibitor G-824. 
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Article 5: Quantitative phosphoproteomic analysis of the PI3K-
regulated signaling network211 
 
Proteomics 
Florian Gnad1, Jeffrey Wallin2, Kyle Edgar2, Sophia Doll3, David Arnott3, Liliane 
Robillard2, Donald S. Kirkpatrick3, Matthew P. Stokes4, Ulka Vijapurkar2, Georgia 
Hatzivassiliou2, Lori S. Friedman2 and Marcia Belvin2 
1 Department of Bioinformatics and Computational Biology, Genentech Inc., South San Francisco, 
CA, USA 2 Department of Translational Oncology, Genentech Inc., South San Francisco, CA, USA
  
3 Department of Protein Chemistry, Genentech Inc., South San Francisco, CA, USA  
4 Cell Signaling Technology, Inc., Danvers, MA, USA 
 
Similar to the MAPK pathway, the PI3K pathway is one of the most frequently 
activated signaling nodes in cancer. Only a few studies have attempted to explore 
the spectrum of phosphorylation signaling downstream of this kinase cascade. Such 
investigations, however, are imperative to understand the mechanisms responsible 
for oncogenic phenotypes. By applying mass spectrometry-based 
phosphoproteomics, we studied the disturbed phosphoproteome after activation or 
inhibition of PIK3CA using isogenic knock-ins and a series of inhibitors, including 
pictilisib (GDC-0941) and taselisib (GDC-0032). 
We uncovered phosphorylation changes in a wide variety of proteins involved in cell 
growth and proliferation, for most of which this was not previously known. Multiple 
phosphoproteome patterns revealed previously undetected feedback, convergence 
and crosstalk between cancer pathways, accentuating the rationale for dual 
pathway inhibition. We provide a dataset rich in potential therapeutic targets 
downstream of the two most important signaling cascades in cancer. 
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Article 6: Region and cell-type resolved quantitative proteomic 
map of the human heart and its application to atrial fibrillation212 
 
Nature Communications 
Sophia Doll1,2, Martina Dreßen3, Philipp Geyer1,2, Dan Itzhak1, Christian Braun4, 
Stefanie Doppler3 , Florian Meier1, Marcus-Andre Deutsch3,5, Harald Lahm3, Rüdiger 
Lange3,5, Markus Krane*,3,5, Matthias Mann*,1,2 
1 Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 
Martinsried, Germany  
2 Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of 
Copenhagen, Copenhagen, Denmark  
3 Department of Cardiovascular Surgery, German Heart Center Munich at the Technische Universität 
München, Munich, Germany  
4 Forensic Institute, Ludwig-Maximilians-University, Munich, Germany   
5 DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 
Germany 
 
The heart is a central organ. It beats approximately 100,000 times a day, precisely 
controlled by the interplay between electrical and mechanical fields. At the 
anatomical level, the heart is composed of four cavities, two septa, four valves, and 
six main vessels, which act in concert to ensure proper filling, ejection, contraction, 
and overall pump function. At the cellular level, the human heart is composed of four 
major cell types.  
While this manuscript does not focus on cancer proteomics, here we combined 
state-of-the-art technologies, such as in StageTip sample preparation, ‘loss-less’ 
nano fractionation, and new MS measurement methods for the first time and apply 
them to map the human heart proteome. Starting with dissected heart samples from 
trauma victims, we performed a tour de force proteomics analysis, which resulted in 
the deepest heart proteome reported to date. Cumulatively, we quantified more than 
11,000 proteins in the heart regions and (for the non-cardiomyocytes) in a cell-type 
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specific manner. Apart from extensive biological and bioinformatic analysis of the 
data, we demonstrate the usefulness of this resource by applying it to atrial 
fibrillation, which revealed distinct mitochondrial dysfunction patterns, opening up 
for a potential future molecular sub-classification. My study was mentioned in the 
Max Planck Institute press release and reached an altmetric score of 161 (meaning 
that my article was in the 98th percentile (ranked 2,277th of the 186,438 tracked 
articles of a similar age in all journals) in only a few weeks after publication in Nature 
Communications. 
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Article 7: Rapid proteomic workflow for solid tumors reveals LSD1 
as a drug target in an end stage cancer patient  
 
In preparation for submission to Molecular Oncology 
Sophia Doll1,2, Maximilian C. Kriegmair3, Alberto Santos Delgado2, Michael Wierer1, 
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Recent groundbreaking advances in MS-based proteomics have set in motion the 
transformation of translational MS-based cancer proteomics from an idea to a 
practice. In this manuscript, we present a rapid proteomic workflow for the analysis 
of clinically relevant cancer tissues allowing quantification of thousands of proteins 
in several hours of measurement time. Applying our workflow to an extremely rare 
cancer type, the urachus carcinoma, we uncovered a potential therapeutic target: 
Lysine specific histone demethylase 1 (LSD1). We created the possibility for medical 
doctors and scientists to truly use proteomics for end stage cancer patients to 
identify additional actionable therapeutic options. 
.  
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Abstract 
Recent advances in mass spectrometry (MS)-based technologies are now set 
to transform translational cancer proteomics from an idea to a practice. Here, 
we present a robust proteomic workflow for the analysis of clinically relevant 
cancer tissues, which allows quantitation of thousands of tumor proteins in 
several hours of measuring time and a total turnaround of a few days. We 
applied it to an extremely rare and chemorefractory urachal carcinoma. 
Quantitative comparison of lung metastasis and surrounding tissue revealed 
several statistically significantly upregulated proteins, among them lysine 
specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic 
regulator and is the target of active development efforts in oncology. This 
demonstrates that clinical cancer proteomics can rapidly and efficiently 
identify actionable therapeutic options even in end stage cancer patients. 
While currently described for a single case study, we envision that it can be 
applied broadly to other patients in a similar condition.  
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Introduction 
Genomic and transcriptomic investigations based on next generation sequencing 
has revolutionized the field of oncology in the last decade and allowed the molecular 
profiling of thousands of tumors in different cancer types (Cancer Genome Atlas 
Research Network et al., 2013; Stratton et al., 2009). While these technologies have 
led to a better understanding of cancer origin and heterogeneity, it has often been 
challenging to turn mutation patterns into actionable therapeutic suggestions. It has 
also become evident that the development and complexity of cancer cannot be 
understood at the genetic or transcriptomic level alone. Clearly, proteins, the driving 
biological entities in cells, also play crucial roles in cancer. So far, proteomics – the 
large scale study of all proteins in a given system - has lagged behind genomics for 
technological reasons. However, following groundbreaking advances in mass 
spectrometry (MS) based proteomics, comprehensive characterization of nearly 
complete proteomes has now become a reality (Aebersold and Mann, 2016; Bekker-
Jensen et al., 2017). In parallel, several proteomic tumor analysis consortia (e.g. 
CPTAC) have been launched and aim to systematically identify and characterize 
cancer-relevant proteins. So far, these consortia have focused on knowledge 
generation, rather than focusing on specific clinical applications. 
Here we set out to use state of the art proteomics technology directly in a clinical 
oncology context. Our group has already established proteomic workflows enabling 
processing of clinically relevant tissue samples to great depth, even for formalin-
fixed paraffin-embedded (FFPE) material (Wiśniewski et al., 2011, 2013). Recently, 
we have combined nearly all sample processing steps in a single reaction tube, 
thereby reducing preparation time, contamination and loss, while increasing 
quantification accuracy (inStageTip method) (Kulak et al., 2014; Doll et al., 2017). 
We reasoned that these advances would now enable rapid analysis of individual 
tumor tissues to inform treatment decisions, especially in patients with rare and end 
stage cancer malignancies, where evidence for therapeutic strategies and clinical 
trials are often lacking. 
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Urachal carcinomas originate from a remnant of the fetal structure connecting the 
allantois and the bladder. This form of cancer is very rare, accounting for less than 
1% of all bladder cancers, aggressive, and consequently little studied. Patients with 
metastatic urachal cancer have poor prognosis and limited treatment options 
(Szarvas et al., 2016). Only a few cases have been investigated at the genomic level 
(Collazo-Lorduy et al., 2016; Singh et al., 2016a) and there are no global protein 
expression profiles of urachal carcinoma that could aid the search for biomarkers, 
therapeutic targets, or disease signatures.  
A 57-year-old female presented with an urachal carcinoma that has metastasized 
to the lungs. The tumor had become refractory to all available chemo or radio 
therapy regimes but the patient wished to continue treatment. Based on the 
inStageTip sample preparation method, we developed a fast and reproducible 
workflow capable of producing analysis results in only about two days. Profiling the 
proteomic landscape of the metastasized tumor in comparison to the normal 
appearing surrounding tissue, we aimed to uncover potential therapeutic targets and 
gain a deeper understanding of the molecular mechanisms underlying this disease 
and its progression. We also employed proteomics to characterize the archived 
primary tumor and compared our results to deep sequencing data that we obtained 
from the same metastases. 
 
Results 
Prior clinical course 
Early symptoms of our patient included gross hematuria, which led us to perform a 
subsequent cystoscopy and bladder biopsy. Histopathology revealed a mucinous 
adenocarcinoma in the bladder, a finding consistent with a diagnosis of urachal 
carcinoma. As a first line of treatment, we performed a partial cystectomy and 
lymphadenectomy. Our final pathology showed a pT3b, pN1, L1, V1, R0 mucinous 
urachal carcinoma of the bladder (Supplementary figure 1A). Follow-up CT scans 
were performed on a three-month basis. Nine months after resection, the CT scan 
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revealed two suspicious hypodense lesions in the liver (Segment 5 and 4a) as well 
as a local recurrence found at the bladder dome (Supplementary Figure 1B and C). 
The local tumor board recommended chemotherapy, including one cycle of XELOX 
(oxaliplatin and capecitabine) and nine cycles of FOLFOX (folinic acid, fluorouracil, 
and oxaliplatin). Chemotherapy led to a partial hepatic response but was stopped 
due to severe peripheral neuropathy. To assess further treatment strategies the 
local recurrence was biopsied and confirmed transurethrally. After tumor board 
consultation, we performed a resection of the local recurrence combined with a 
partial hepatectomy and subsequent radiotherapy of the local recurrence side 
(59,4Gy). In later stages, two metastases were diagnosed at the introitus vaginae 
and the CT-scan of the thorax revealed bilateral noduli. Subsequent chemotherapy 
with four cycles of Gemcitabine/Cis-Platin led to a mixed response and further 
pulmonary progression of a predominant singular nodule was diagnosed (Figure 
1A). At this point, all standard treatment options were exhausted and we set out to 
resect the lung metastasis and surrounding healthy tissue for subsequent proteomic 
analyses. Due to medical and psychological issues the resection was delayed for 
two months. In the thoracoscopy a disseminated pleural carcinosis was observed, 
that was most likely covered by pleural effusion in the preoperative CT-scan (Figure 
1B). Pleural metastases and healthy pleura were biopsied, washed in PBS, flash 
frozen, and immediately transferred for proteomic analyses within one day. 
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Figure 1 Preoperative CT-scans of the urachal carcinoma patient. A) CT scan in March 
2017 showing a main metastases in the lungs. B) CT scan in June 2017 depicting a pleural 
effusion before the surgery, hiding a pleural carcinosis. 
 
Streamlined proteomics workflow applied to chemorefractory carcinoma 
To be useful in a clinical oncological setting, we reasoned that a proteomics 
workflow need to fulfill several criteria, including rapid overall analysis time (few 
days), extreme sensitivity (few thousand cells), depth of quantitative proteome 
coverage (several thousand proteins) along with robustness and reproducibility. The 
workflow that we adapted fulfills all these criteria (Methods): Briefly, we performed 
all sample preparation in a single reaction vial, based on the in-StageTip (iST) 
method sample preparation (Kulak et al., 2014). We chose a single-run LC-MS/MS 
workflow, rather than pre-fractionating the sample, to minimize measurement time 
and maximize quantitative accuracy. All bioinformatic analysis was done in the freely 
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available MaxQuant and Perseus software environments (Cox and Mann, 2008; 
Tyanova et al., 2016). 
Upon shipment of the samples in the late afternoon, we started by lysing the 
samples and extracting the proteins. The surrounding fat of the tissues were 
removed by high speed centrifugation. Proteins were subsequently digested over-
night using proteases. On the following day, we analyzed the peptide mixtures using 
a state-of-the-art label free workflow on a quadrupole – Orbitrap mass spectrometer 
(Figure 2B). Each sample, constituting a few µg of material, was measured in single 
shot triplicate measurements using 100 min high-performance liquid 
chromatography (HPLC) gradients. Analysis in MaxQuant specified a false 
discovery rate (FDR) of less than 1% at the peptide and protein levels. In total, we 
identified 50,870 sequence-unique peptides, corresponding to 5,562 protein groups 
(proteins that can be distinguished based on the available peptide information). The 
MaxLFQ algorithm (Cox et al., 2014) quantified 5,543 proteins in total and similar 
coverage in all samples. For further analysis, we only considered the subset of 4,857 
proteins in our data with quantitative values with at least 70% valid values across 
the samples. Mean sequence coverage of all proteins by identified peptides was 
about 25%. Signal intensities for the quantified proteins spanned about five orders 
of magnitudes, with hemoglobin as one of the most abundant proteins, despite 
extensive washing of the samples with PBS before sample processing. Quantitative 
reproducibility was excellent, demonstrated by Pearson correlation coefficients 
between 0.97-0.99, and was on par, or even exceed the values we previously 
achieved in cell lines systems (Coscia et al., 2016). We likewise observed high 
correlation values between control tissues taken from different locations (0.92) and 
between two different samplings of the metastases (0.97). Raw data and MaxQuant 
results are provided online and are available in our proteomic database MaxQB 
(Schaab et al., 2012). The complete workflow can be performed in less than 2.5 
days and we conclude that it is well suited to application in the clinic. 
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Figure 2 Case study proteomics workflow. A) Timeline of the project. B) Experimental 
design, including source of material, inStageTip sample preparation, and depiction of the 
analytical workflow. 
 
Proteome analysis reveals LSD1 as a potential therapeutic target 
For a functional view of the proteomic data, we used volcano plots – a type of scatter 
plot often used to present large-scale proteomic data sets - to compare expression 
differences between lung pleural metastases and healthy-appearing pleura. Based 
on a t-test for binary comparison and employing a 5% FDR, we found that 108 
(2.2%) proteins showed significant alteration, of which 47 displayed significant up-
regulation and 61 down-regulation in the metastases. Gene set enrichment analysis 
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(GSEA) using gene set collections from the MSigDB (Subramanian et al., 2005) 
revealed that proteins upregulated in the metastases were significantly enriched 
(p<5e-6) for the terms epithelial mesenchymal transition, tumor invasiveness, and 
tumor metastasis. For example, periostin (POSTN) has previously been reported to 
promote cell motility in several cancer types, was 13-fold higher expressed in the 
metastases compared with non-diseased tissue (Gillan et al., 2002; Ishiba et al., 
2014; Mikheev et al., 2015). The most up-regulated (>100-fold) protein in the 
metastases was thrombospondin-2 (THBS2) and is also involved in cell invasion as 
well as angiogenesis and correlates with poor survival (Bornstein, 2009; Iruela-
Arispe et al., 2004; Lin et al., 2016; Qian et al., 2017; Wang et al., 2016). Another 
protein driving cell invasion, methylthioribose-1-phosphate isomerase (MRI1) was 
highly significantly upregulated but only 1.9-fold (Kabuyama et al., 2009). These 
observations demonstrate that the proteomics experiment performed as expected 
and suggest an important role of these proteins in the metastatic progression of 
urachal carcinoma. 
In contrast, downregulated proteins were very significantly enriched in mitochondrial 
proteins (p < 1e-17), such as pyruvate carboxylase (PC), Acetyl-CoA carboxylase 2 
(ACACB), and Acyl-coenzyme A thioesterase 2 (ACOT2). Interestingly, Ras 
suppressor protein 1 (RSU1) was about 4-fold down-regulated in the metastases. 
Apoptosis-inducing factor 2 (AIFM2) was 28-fold down-regulated in the metastases 
compared with non-diseased tissue. These observations suggest a regulatory role 
of RSU1 and AIFM2 in urachal carcinoma metastases. 
In an effort to derive therapeutic options, we first reduced the total number of 
significantly upregulated proteins by applying a more stringent cutoff (1% FDR). This 
yielded four significantly upregulated proteins in the metastatic tissue: 
methylthioribose-1-phosphate isomerase (MRI1), solute carrier family 22 member 
18 (SLC22A18), collagen alpha-1 (XI) chain (COL11A1), and lysine-specific histone 
demethylase 1A (KDM1A, also known as LSD1) (Figure 3A). Next, we asked which 
of these proteins were potentially druggable, which left us with LSD1 as the sole 
remaining candidate. We quantified LSD1 with 11 unique peptides, reaching an 
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approximate sequence coverage of 20%, and found that it was 16-fold more highly 
expressed in the metastases compared to the control.  
LSD1 is an epigenetic regulator that demethylates both the activating histone mark 
H3K4me and the repressive mark H3K9me, thereby acting as a coactivator or 
corepressor, depending on cellular context. LSD1 has previously been reported as 
upregulated in multiple cancer types and its inhibition has antitumor activity in lung 
cancer (Mohammad and Kruger, 2016; Singh et al., 2015). These findings led to the 
development of multiple LSD1 inhibitors that are currently in clinical trials (Alsaqer 
et al., 2017; Mohammad and Kruger, 2016; Schmidt and McCafferty, 2007). Even 
though it was unclear whether the lung metastases would respond to a LSD1 
inhibitor, there were no other rational or reasonable treatment options available at 
this point.  Unfortunately, extensive efforts to obtain one of these drugs for use in 
our patient ultimately proved unsuccessful. Luckily, tranylcypromine a drug 
developed decades ago and FDA approved for the treatment of depression and 
anxiety (Burger and Yost, 1948) has recently been shown to irreversibly inhibit LSD1 
as a side effect (Binda et al., 2010; Ulrich et al., 2017; Zheng et al., 2016). This 
analogue of amphetamine is a monoamine oxidase (MAO) inhibitor, an enzyme 
family that is mechanistically related to LSD1. Tranylcypromine and derivates of this 
drug already showed clinical efficacy for several condition in clinical trials, including 
the treatment of AML. The local tumor board approved treatment approved 
treatment with this drug and our patient was prescribed a tyramine-free diet, to 
prevent accumulation of tyramine (which is normally metabolized by MAO) leading 
to high blood pressure, which may culminate in a hypertensive crisis (Gillman, 2011; 
Ulrich et al., 2017). However, a baseline CT at the initiation of therapy revealed 
dramatic metastatic progression to the liver, concurrent with hepatic failure 
(Supplementary Figure 1D). The patient was then transferred to palliative care ward 
and died soon after. 
MS-based proteomics is a multifaceted technology and further allowed us to 
investigate the plasma proteome of our patient. Based on our previously developed 
‘plasma proteome profiling’ pipeline (Geyer et al., 2016a) we quantified 
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approximately 460 proteins in triplicate LCMS measurements enabling 
quantification of inflammatory proteins, such as CRP and the majority of the 
complement system (Supplementary Figure 2). Furthermore, we identified the entire 
inflammatory panel which we have previously reported and found it to be clearly 
elevated compared to normal controls (Geyer et al., 2016b), as expected in a patient 
with end-stage malignancy and heavy metastatic load. 
We also investigated whether the patient would be likely to respond to 
immunotherapy. MS-based measurements did not reveal any expression of PD1 or 
PDL1 proteins, an observation that was later confirmed by immunohistochemistry 
(Supplementary Figure 3D). We also did not observe any immune cells infiltration in 
the metastases, suggesting a poor response to immunotherapy-based treatments. 
 
 
Figure 3 Proteins differentially expressed in the urachal carcinoma lung metastases. 
A) Volcano plot of the p-values (y-axis) vs. the log2 protein abundance differences (x-axis) 
between metastases and control, with lines of significance colored in black or grey lines 
corresponding to a 5% or 1% FDR, respectively. B) Mechanisms of action of LSD1/KDM1A. 
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Proteomic analysis of the primary tumor 
To further investigate the proteomic landscape of our quantitative and in depth 
proteomic case study, we next analyzed the proteome of the primary tumor, which 
had been preserved as FFPE material for several years. H&E staining revealed that 
the primary tumor was rich in extracellular mucin and stroma compared to healthy 
control tissue (Figure 4B and C). Our proteomic analysis revealed major differences 
between the primary and healthy surrounding tissue (Figure 4A). In total, we 
quantified approximately 4,300 proteins and found that mucinous (MUC1 and 
MUC2) and mesenchymal proteins (such as THBS2, COL11A1, and CTHRC1) were 
significantly upregulated in the primary tumor compared to healthy surrounding 
tissue. Generally, the epithelial mesenchymal transition, and thus mesenchymal 
gene upregulation is associated with poor prognosis in various malignancies 
including colorectal cancer and ovarian cancer (Chen et al., 2014; Rokavec et al., 
2017; Sleeman and Thiery, 2011). The fact that mesenchymal proteins were highly 
enriched in the primary tumor, is concordant with the later development of multiple 
and aggressive metastases. Interestingly, we also found that LSD1 appeared to be 
upregulated in the metastases compared to the primary tumor, albeit not 
significantly. 
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Figure 4 Differentially expressed proteins in the primary tumor. A) Volcano plot of the 
p-values vs. the log2 protein abundance differences between primary tumor and control, 
with significance lines (5% FDR) colored in black. B) H&E stainings of healthy control tissue 
surrounding the primary tumor (C), reveals prominent stroma formation. 
 
Next generation sequencing analysis of the metastases 
To gain additional insights into the overall molecular mechanisms underlying 
urachal carcinoma, tumor etiology and to compare transcriptomics to proteomics, 
we also extracted RNA and DNA extraction for subsequent next generation 
sequencing. The quality of the extracted RNA from the metastatic samples, 
however, was poor, prohibiting transcriptomic analysis. DNA is more stable, allowing 
us to perform exome sequencing on our sample. Overall, we observed hundreds of 
mutations in coding regions, indicating a hypermutated phenotype, consistent with 
a previous report (Kardos et al., 2017). Comparing the mutations to a database of 
druggable genes (Broad Institute), yielded a total of 160 mutations of potential 
therapeutic interest. Among those, we examined the mutation spectrum of the 
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growth factor receptor (EGFR) as EGFR-inhibitors (e.g. gefitinib), have been 
described for urachal carcinoma recently (Collazo-Lorduy et al., 2016; Singh et al., 
2016b; Sirintrapun et al., 2014). The EGFR pathway member K-RAS is frequently 
mutated in urachal cancer and we identified a missense mutation at position 117 
(K117N, exon 4) that has previously been associated with various cancers forms 
such as bladder and colorectal cancer. Unfortunately, multiple studies reported that 
patients with K-RAS mutations in exons 2, 3 and 4 did not respond to EGFR-
targeted therapy (Bokemeyer et al., 2015; Douillard et al., 2013). We also found two 
intronic and two exonic somatic mutations of the LSD1 gene, which, however, 
scored neutral by mutation effect predictors (Supplementary Figure 4). 
 
Discussion 
Modern oncology is at a turning point, where systemic cancer treatment is moving 
from multi-cytotoxic chemotherapies towards individual targeted therapies. This is 
particularly promising for patients suffering from rare cancer forms, where standard 
chemotherapies often fail and large clinical studies are unlikely to be performed. In 
the near future, sequencing at the genomic, transcriptomic and proteomic levels 
might provide the basis for individual targeted treatment prescription and thereby 
change clinical practice. However, the large spectrum of mutations does not 
necessarily lead to clear therapeutic options, a problem that becomes even more 
acute when considering mutational heterogeneity of most tumors. These general 
challenges were reflected in our case study, where mutational analysis did not lead 
to a clear treatment recommendation. In contrast, our personalized MS-based 
proteomic analysis worked robustly and quickly on both the lung metastases and 
the archived primary tumor.  
The current standard treatment for localized urachal cancer is surgery, whereas 
chemotherapy is used on the metastatic disease. Given the rarity of this cancer type, 
robust data from prospective trials on chemotherapy regimens is unlikely to be 
obtainable and evidence mainly consists of small retrospective cohorts. Due to the 
similarity of urachal cancer to colorectal adenocarcinoma and urothelial carcinomas, 
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treatment regimens are generally extrapolated from these diseases, justifying the 
FOLFOX therapy prescribed to our patient. Targeted epidermal growth factor 
receptor (EGFR)-inhibitors (e.g. gefitinib), have been prescribed for urachal 
carcinoma recently. To guide decisions concerning this alternative therapy option, 
we further looked into K-RAS mutations and uncovered a missense mutation. 
However, EGFR-targeted therapy was not prescribed because multiple studies 
reported that patients with similar K-RAS mutations as our patient, did not respond 
to therapy (Bokemeyer et al., 2015; Douillard et al., 2013). Furthermore, the 
elevated liver enzymes of our patients were contraindicated such a therapy. In the 
search for possible treatment options in this patient, we found that PDL1 and CD8 
immunohistochemistry were also negative, suggesting a poor response to check-
point inhibitors.  
Lacking evidence-based treatment options for our end-stage patient, who was 
willing to exhaust all possibilities, we turned to our MS-based proteomic analysis, 
which identified LSD1 as a therapeutic target highly enriched in metastatic tissue, 
thus providing a promising treatment opportunity. Of note, our workflow allowed fast 
proteomic analysis of clinical tumor tissue providing timely results to the patient and 
the clinicians. The proteomic sample preparation and data analysis were 
accomplished in only about two days, faster than the genomic analysis. This 
highlights the promise of MS-based proteomics in clinical routine, where fast target 
identification for cancer patients beyond standard treatment could be highly 
beneficial. 
In summary, we demonstrated a fast and reproducible proteomic workflow that 
created the possibility for clinicians to use proteomics for personalized diagnosis 
and treatment in the clinical setting. By combining genomic with proteomics data, 
we further informed the therapeutic decision. We aim to apply this workflow to 
cancer patients in a variety of chemorefractive tumors, in the hope of identifying 
additional treatment options for at least some of them. 
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Supplementary Figures 
 
 
Supplementary Figure 1: A) MR-imaging of the primary tumor showed a suspicious mass 
at the anterior bladder wall (red circle). B-C) Follow-up CT-imaging revealed local 
recurrence nine months after partial nephrectomy (red circle) and a hepatic metastasis (red 
arrow). D) Massive progression of hepatic metastases in the CT scan prior to LSD1 therapy. 
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Supplementary Figure 2: Plasma proteome abundance rank. The previously reported 
inflammatory panel is highlighted in red, other complement proteins are represented in blue. 
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Supplementary Figure 3: H&E stainings. A) Healthy urothelium of the partial cystectomy 
specimen. B) Primary mucinous urachal adenocarcinoma. C-D) Hepatic metastasis of the 
urachal carcinoma with negative PDL1 immunohistochemistry. 
 
 
 
Supplementary Figure 4: Mutation diagram of LSD1. 
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Material and methods  
Sample preparation for mass spectrometry analysis 
The lung metastases were collected during surgery and were washed three times 
with cold PBS before flash freezing the samples in liquid nitrogen and shipping on 
dry ice. The samples were cut in half to enable genomic and proteomic analysis. 
Proteomic sample preparation 
Control and lung metastases samples were thawed on ice and prepared according 
to the in stage tip sample preparation method (Kulak et al. Nat Methods, 2014). 
Briefly, 100 µl of the reducing alkylating sodium deoxycholate buffer (PreOmics) was 
added to the samples before protein denaturation at 100°C for 20 min. Proteins were 
then digested by LysC and trypsin overnight at 37°C and 1700 rpm. Peptides were 
acidified to a final concentration of 0.1% trifluoroacetic acid (TFA) for SDB-RPS 
binding and desalted before LC-MS/MS analysis.  
 
Liquid chromatography-MS analysis 
Samples were measured on an on a quadrupole Orbitrap mass spectrometer 
(Scheltema et al., 2014; Kelstrup et al., 2014) (Q Exactive HF, Thermo Fisher 
Scientific, Rockford, IL, USA) coupled to an EASYnLC 1200 ultra-high-pressure 
system (Thermo Fisher Scientific) via a nano-electrospray ion source. About 1 µg of 
peptides were loaded on a 40 cm HPLC-column (75 μm inner diameter; in-house 
packed using ReproSil-Pur C18-AQ 1.9 µm silica beads; Dr Maisch GmbH, 
Germany). Peptides were separated using a linear gradient from 3% to 23% B in 82 
min and stepped up to 40% in 8 min at 350 nl per min where solvent A was 0.1% 
formic acid in water and solvent B was 80% acetonitrile and 0.1% formic acid in 
water. The total duration of the gradient was 100 min. Column temperature was kept 
at 60 °C by a Peltier element-containing, in-house developed oven. The mass 
spectrometer was operated in ’top-15’ data-dependent mode, collecting MS spectra 
in the Orbitrap mass analyzer (60,000 resolution, 300-1,650 m/z range) with an 
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automatic gain control (AGC) target of 3E6 and a maximum ion injection time of 25 
ms. The most intense ions from the full scan were isolated with a width of 1.4 m/z. 
Following higher-energy collisional dissociation (HCD) with a normalized collision 
energy (NCE) of 27%, MS/MS spectra were collected in the Orbitrap (15,000 
resolution) with an AGC target of 1E5 and a maximum ion injection time of 25 ms. 
Precursor dynamic exclusion was enabled with a duration of 20 s.  
 
MS data analysis 
Tandem mass spectra were searched against the 2015 Uniprot human databases 
(UP000005640_9606 and UP000005640_9606_additional) using MaxQuant 
version 1.5.3.34 with a 1% FDR at the peptide and protein level, peptides with a 
minimum length of seven amino acids with carbamidomethylation as a fixed 
modification and N-terminal acetylation and methionine oxidations as variable 
modifications. Enzyme specificity was set as C-terminal to arginine and lysine using 
trypsin as protease and a maximum of two missed cleavages were allowed in the 
database search. The maximum initial mass tolerance for precursor and fragment 
ions were 4.5 ppm and 20 ppm, respectively. If applicable, peptide identifications by 
MS/MS were transferred between runs to minimize missing values for quantification 
with a 0.7 min window after retention time alignment. Label-free quantification was 
performed with the MaxLFQ algorithm using a minimum ratio count of 1. 
 
Statistical analysis 
Statistical and bioinformatics analysis was performed with the Perseus software 
(Tyanova et al., 2016) (version 1.5.5.0), Microsoft Excel, and R statistical software. 
Proteins that were identified in the decoy reverse database or only by site 
modification were not considered for data analysis. Mean log2 ratios of biological 
triplicates and the corresponding p-values were visualized with volcano plots. We 
used t-test for binary comparisons and SAM with s0=0.1 and FDR<0.05 for the 
assessment of t-test results in volcano plots. 
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IV) Discussion 
 
Approximately nine million deaths worldwide are attributed to cancer, and its poor 
clinical outcome is related to a diverse array of factors, including late diagnosis, lack 
of specific treatment, therapy resistance, and the limited connection of pre-clinical 
with clinical research. Many cancer subtypes remain poorly understood and few 
targeted therapeutic treatments are available. Revolutionary advances in genomics 
technologies have so far mainly contributed to our understanding of cancer origin 
and heterogeneity but unfortunately not had much impact on the clinic. In parallel, 
technology improvements in MS-based proteomics now finally enable the analysis 
of the molecular drivers of cellular function – proteins. These advances enable the 
identification and quantification of nearly complete proteomes, as more than 10,000 
proteins and PTMs can be identified in cells and tissues, including challenging 
muscle tissues (Article 6). It is therefore possible to use MS-based proteomics to 
study cellular changes at a near comprehensive, systems-wide level by examining 
changes in protein and PTM expression, protein subcellular localization and protein 
interaction partners. 
To address the fundamental question of how the genotype is mechanistically 
translated into phenotype it is important to interrogate the role of specific genes, for 
instance by deleting or inserting a gene or mutation of interest, on a global proteomic 
and phosphoproteomic scale (Articles 4 and 5). Likewise, with small molecule 
inhibitors we can investigate the perturbation of phosphorylation signaling cascades 
following kinase inhibition, on a systems-wide scale (Article 3). For example, a 
recent study showed that cancer driven alterations in human tumors can be mapped 
in human cancer cell lines and correlated with drug treatment sensitivity213. Cell line 
models could therefore be used in the future to guide and link the development and 
application of therapies in the clinic. 
Further proteomic developments now permit in-depth tissue analysis in about two 
days from obtaining the sample to final analysis result, this speed being a 
prerequisite for clinical application (Article 7). Based on such a rapid proteomic 
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analysis, we uncovered a potential therapeutic target in a chemorefractory cancer 
patient, which enabled clinicians devise a third line treatment. We envision that this 
workflow can be applied to cancer patients at much earlier stages of disease 
progression, with the ultimate goal to distinguish patients most likely to respond and 
benefit from a given treatment from those who will only endure its negative side 
effects. 
Together, the technical advances detailed in this thesis lead us into a new paradigm, 
in which MS-based proteomics is transformed from being a tool for specialist 
laboratories to a powerful technology for translational cancer proteomics used in 
cutting edge clinics to deliver personalized treatment options. 
Building on the work presented here, we aim to expand our robust, rapid and 
sensitive proteomic workflow to the analysis of human cancer tissues at both greater 
depth and higher throughput and accuracy. We plan to apply this workflow to micro- 
and macro-dissected cancer tissues in an automated fashion to explore the 
proteome of large FFPE cancer tissue cohorts found in multiple biobanks as well as 
biopsies collected during surgery. By facilitating the analysis of thousands of 
samples in a reasonable timeframe, one could study the underlying molecular 
mechanisms of cancer at the proteome level, testing the validity of known 
biomarkers, while potentially uncovering new ones. In two preliminary studies, we 
have already analyzed the proteome of 60 melanoma FFPE samples and adenoma 
samples, which yielded relevant results. 
To achieve more reproducible measurements (which is a prerequisite in clinical 
practice) we envision using data independent acquisition (DIA) measurement 
strategies. DIA has become particularly attractive with the latest technological 
developments, predominantly the sequencing speed and sensitivity of the latest 
Orbitrap instruments214. With the latest instrumentation, DIA largely eliminates the 
missing value problem. It also provides the means to couple MS to fast LC 
separation techniques. The recently developed Evosep LC, which is based on a 
rapid elution concept215, significantly reduces the overhead time between sample 
pick up and MS measurement start point. This new design of LC makes use of a 
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pre-formed gradient that already contains the sample. Furthermore, sample to 
sample carry over, and thus contamination, is considerably reduced as peptides are 
loaded on disposable StageTips, which are used for direct elution of the samples. 
Based on a 90 min method, one can reach a throughput of up to 16 tissue samples 
per day and instrument. Chemical multiplexing, such as in 11-plex TMT would 
enable an even higher throughput, enabling direct comparison of samples in the 
same spectrum. This might obviate the need for technical triplicate measurements 
that are still often used in label free approaches to ensure high accuracy. This 
combination of robustness and performance technologies would make it possible to 
tackle clinical studies at relatively high throughput. 
The integration with various omics approaches, such as in proteogenomics, will play 
even more important roles in cancer research and metabolomics also holds great 
promise for precision surgery in particular. This will generate exponential data flows 
that will necessitate concurrent advances in bioinformatics and computational 
proteomics. Machine-learning technologies have the power to uncover cancer 
drivers and facilitate the ability to generate biological insights from large datasets. 
The integration of large scale omics data sets have led to a new era of data-driven 
medicine, termed high definition medicine216. Likewise, in a truly personalized 
medicine approach, one would begin by determining the personal healthy baseline 
of an individual to later ascertain the exact pathology in a patient-resolved fashion. 
In cases where this is not possible, one can at least establish typical reference 
ranges, as we have begun to do with the proteome of a healthy human heart (in this 
case, compared to diseased atrial fibrillation hearts) (Article 6). On a global scale, 
large data sets would also enable better prevention and treatment options if these 
big data are managed more effectively. Apart from improving the health of millions, 
this could result in billions of dollar savings to health care systems, as better 
management of current clinical trials could allow more efficient data sharing and 
advance clinical trials more rapidly217. 
In my journey from analyzing a single protein through a comprehensive 
understanding of deep proteome networks, I also explored the scientific 
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interconnections between industry, academia, and the clinic during my PhD. It is my 
hope that collaborations between these different institutions will play increasingly 
crucial roles in the future to develop more effective and affordable drugs, manage 
big data and fight cancer more efficiently.  
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